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Abstract
Review of the current literature reveals inconsistent findings on potential
associations between antidepressant use during pregnancy and adverse fetal and child
health and development. This study aims to examine the effect of antenatal SSRI
exposure on several neonatal (preterm birth, small- and large-for-gestational age, Apgar
score, and neonatal intensive care unit admission) and child developmental outcomes
(measured by Ages and Stages Questionnaire) while controlling for confounding by
indication. Data were obtained from the Prenatal Health Project, a longitudinal cohort
study of 2,357 women in London, Ontario. Results from univariable analysis discovered
that infants exposed to in utero SSRIs were more likely to be large-for-gestational age
compared to infants of women exposed to antenatal depressive symptoms but not SSRIs
and to infants of women unexposed to either antenatal depression or SSRIs. The small
sample size of the antidepressant-exposed population limited our study and further
research is warranted to verify the significance of our findings.
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Chapter 1: Introduction, Rationale, and Objectives
The decision to take medication during pregnancy is a challenge faced by many
pregnant women as all medications may potentially carry a risk of harming the
developing fetus. This is certainly the case for depressed women determining whether or
not to take antidepressant treatment during pregnancy. In order to assist women with
evidence-based decisions, researchers and clinicians are faced with different challenges
of assessing the risks and benefits of antidepressant treatment against the risks of
untreated depression on the developing fetus. Even with the considerable amount of
research, however, the risk of antidepressant treatment during pregnancy on the fetus and
child development has been unclear [1, 2].
Due to ethical limitations in conducting randomized controlled trials (RCTs), all
human studies to date that examined the safety and efficacy of antidepressant medication
use during pregnancy on the subsequent neonatal and child development outcomes have
been observational [3]. There are many challenges and limitations in designing an
observational pharmacoepidemiological study in this field as well. The main challenge is
in separating the effects of antidepressant use during pregnancy from the effects of
underlying maternal antenatal depression on the outcomes of interest, since both have
been individually found to be associated with adverse neonatal and long-term child
developmental outcomes.
Therefore, the main goal for this thesis is to differentiate the effects between
antenatal depression and in utero SSRI exposure on neonatal and child developmental
outcomes. The majority of study designs in which outcomes of antidepressant exposure
were investigated did not distinguish the effect of antenatal antidepressant use from any
risk attached to the medical indications for antidepressant use, such as depression. Rather,
studies have tended to compare an antidepressant exposure group to only the nonexposed group, which results in confounding by indication.
In this thesis, we will use a well-established prenatal cohort [4] in which data
were collected prospectively. This allows us to design our study to reduce confounding
by indication. In particular, we directly compare neonatal and child outcomes between
those whose mothers had antenatal antidepressant use and antenatally depressed mothers
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without antidepressant use, while using a group with neither exposure as the base
comparison group. To our knowledge, only a small number of studies have this direct
comparison for neonatal outcomes [5-8] and long-term developmental outcomes [9-13].
It is anticipated that this study will contribute to our understanding of the risks
versus benefits of antidepressant use during pregnancy, in comparison to untreated
antenatal depression. As this literature evolves, it will assist health care professionals in
making evidence-based decisions.
1.1 Research Objectives
The primary goal of this project is to examine the neonatal and long-term
developmental outcomes of antidepressant use, with special interest in SSRI use during
pregnancy in women from London, Ontario, by using secondary data source from
Prenatal Health Project (PHP). The specific objectives of this thesis project are as
follows:
1. To describe the baseline characteristics of mothers who fit in the following study
groups antenatally: 1) Antidepressant group: those who take antidepressants for
any indication (indication unknown); 2) SSRI subgroup: those who take SSRIs; 3)
Depressive Symptoms group: those who have elevated depressive symptoms but
do not take antidepressants and; 4) Reference group: those who do not have
elevated depressive symptoms and do not take antidepressants.
2. To compare neonatal outcomes among the study groups. Specific neonatal
outcomes of interest are: preterm delivery, small-for-gestational age (SGA), largefor-gestational age (LGA), Apgar scores at one (Apgar-1) and five (Apgar-5)
minutes, and NICU admissions.
3. To compare long-term development of toddlers and preschoolers (measured by
Ages and Stages Questionnaire) among the study groups.
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Chapter 2: Literature Review
2.1 Overview
The structure of this chapter outlines the characteristics and consequences of
antenatal depression and antidepressant use during pregnancy, as well as the individual
effect of both on neonatal and child development outcomes. It should be noted that this
literature review will mainly focus on selective serotonin reuptake inhibitors (SSRIs) as
they are the most studied, prescribed, and used antidepressant in our focused population.
2.2 Depression during Pregnancy: Characteristics and Consequences
2.2.1 Depression during Pregnancy: Prevalence
Pregnancy was generally believed to be protective against depressive disorders
and thought to be associated with the state of emotional well-being [14]. However,
evidence for this claim is sparse and many women have increased risk of developing
and/or sustaining depressive disorders during pregnancy [14]. In fact, the first onset peak
of depression for women is during the childbearing years [15]. According to the a metaanalysis conducted by Agency for Healthcare Research and Quality (AHRQ) [16], the
point prevalence for combined major and minor depression during pregnancy was
estimated to be 8.5 to 11.0 percent (3.1 to 4.9 percent for major depression alone) while
the period prevalence of depressive disorder estimated from conception to birth was 14 to
23 percent. Bennett et al. [17] reported that the prevalence of depression increases from
7.4% in the first trimester to 12.8% in the second and 12.0% in the third trimester.
Additionally, depression is a highly recurrent disorder and the risk of depressive relapse
during pregnancy for women with a history of depression is approximately 43% [14].
Therefore depression is a prevalent condition affecting many women during pregnancy,
notably more prevalent in disadvantaged groups such as young, single women with
limited socioeconomical support [18].

2.2.2 Symptoms and Consequences of Antenatal Depression
Many pregnant women suffering from depression are often not recognized, or
diagnosed, and subsequently not treated due to the similar features of depression and
normal physiological and hormonal changes that occur during pregnancy such as changes
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in mood, appetite, and sleep pattern [19]. The symptoms of antenatal depression are
persistent low mood, loss of interest in daily activities, dramatic change in appetite,
emotional disconnects with the unborn, negative thoughts, lack of self-care, and serious
thoughts of suicide in severe cases [20, 21]. The consequences of these symptoms may
lead to non-adherence to antenatal care, tobacco, alcohol, and drug use, poor weight gain
or loss, poor nutrition, anxiety (strongly comorbid with depression), psychotic symptoms,
preeclampsia, and post-partum depression [21, 22]. Despite the consequences and high
prevalence of antenatal depression, many depressed pregnant women are under-treated or
not treated at all [18, 23]. In a national survey, Dietrich et al. [24] found that fewer than
half of obstetricians stated that residence training equipped them with the knowledge and
training to recognize and treat depression. Additionally, the risk factors are not readily
recognized [24].

2.2.3 Antenatal Depression Screening Tools
Early detection of antenatal depression improves the chances of effective
treatment of depression and may prevent major depressive disorder (MDD) [25].
Therefore, the American College of Obstetricians and Gynecologists (ACOG) endorses
screening for depressive symptoms at least once during pregnancy using a validated tool
[26]. One of the most widely used and validated depression screening tools in antenatal
research is the Center for Epidemiologic Studies Depression Scale (CES-D) [25, 27]. As
well, it is recommended as part of the initial assessment for antenatal depression [25].
The CES-D measures the depressive symptoms (cognitive, somatic, affective, and
behavioural) experienced by the participant in the past week [27]. The scale has 20 items
and the score ranges from 0 to 60. A cut-off point of ≥16 is typically used to indicate
clinical depression with a sensitivity and specificity of 60% and 92%, respectively [27].
Other tools such as the Edinburgh Postnatal Depression Scale (EPDS), Beck
Depression Inventory (BDI), the BDI-II, the Patient Health Questionnaire-2 (PHQ-2),
and the Pregnancy Depression Scale (PDS) are also implemented in antenatal health
studies [25]. It is important to note that these tools do not serve as diagnostic tests for
depression but rather indicate depressive symptoms and the possible risks of developing
depressive disorder. To be clinically diagnosed with MDD by a physician, the patient
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must fit the diagnostic criteria as described in the Diagnostic and Statistical Manual of
Mental Disorders 5th edition (DSM-5), which includes depressed mood or loss of pleasure
in all or most of one’s usual activities for more than 2 weeks and have experienced at
least 5 out of 9 specific clinical features (depressed mood, significant weight change,
insomnia or hypersomnia, suicidality, etc.) for nearly every day [28].

2.2.4 Antenatal Depression Risk Factors
Antenatal depression is associated with many factors including sociodemographic
status, psychiatric comorbidities, life stresses, relationship quality, social support,
substance abuse, and obstetric history [29]. A systematic review performed by Lancaster
et al. [29] set out to identify the risk factors for antenatal depression that can be assessed
in routine obstetric care. From 57 studies, they found that life stress, lack of social
support, and domestic violence to be the strongest correlates with antenatal depression in
their multivariable analyses. On the other hand, maternal anxiety, history of depression,
unintended pregnancy, lower income, lower education, smoking, single status, and poor
relationship quality were strongly associated with antenatal depression in their bi-variable
analyses. Pregnant women with these risk factors are considered at high risk of
developing antenatal depression and should be screened for depressive symptoms.

2.2.5 Antenatal Depression: Adverse Neonatal Outcomes
Depression during pregnancy has negative health consequences for both the
mother and child. Antenatal depression has been found to be associated with increased
risk of adverse neonatal events such as preterm delivery [30, 31], low birth weight [30,
31], intrauterine growth restriction (IUGR) [32, 33], and admissions to Neonatal
Intensive Care Unit (NICU) [33]. The postulated mechanism is the dysregulation of the
hypothalamic-pituitary adrenal axis (HPA-axis), sympathetic nervous system, and
inflammatory system [34]. The increased secretion of maternal stress hormones such as
corticotrophin releasing hormone, cortisol, and catecholoamines may directly or
indirectly impact fetal development and epigenetically program the HPA-axis of the fetus
via DNA methylation, which could potentially have long-term developmental
consequences as well [35, 36]. In addition to the biological mechanisms, pregnant women
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with depressive symptoms are also less likely to take care of themselves or to attend to
antenatal care, and more likely engage in unhealthy lifestyle behaviours such as smoking
and alcohol consumption that exacerbate the risk of adverse pregnancy outcomes [1, 35].
Numerous studies have examined the relationship between antenatal depression
and adverse neonatal outcomes; however, many of these studies have methodological
limitations due to lack of proper controls for confounders and size sample issues. In
addition, the heterogeneity of study design further complicates the comparability of
results [35]. The confounders that are inadequately controlled in most studies are the
severity of depression, demographic factors, substance abuse, and comorbid psychosocial
factors such as anxiety and self-reported stress [30, 35, 37]. Therefore, the findings for
adverse neonatal outcomes such as preterm delivery, low birth weight, small-forgestational age (SGA), low Apgar score, and admission to NICU are inconsistent.
Szegda et al. [35] critically reviewed studies that investigated antenatal
depression and adverse neonatal outcomes including preterm birth, low birth weight, and
SGA. Out of 27 studies, 12 found that antenatal depression, particularly early to midpregnancy, increased the risk of preterm birth with an odds ratio (OR) range of 1.3 to 4.9.
The association between antenatal depression and low birth weight was less consistent as
only 6 out of 20 studies discovered an increased risk with OR range of 1.4 to 2.2. An
increased risk of SGA in infants exposed to antenatal depression, particularly during
early to mid-pregnancy, was found in 5 out of 10 studies. A meta-analysis conducted by
Grote et al. [30] gathered 29 prospective observational studies (n=48,004) and calculated
the pooled relative risk. They found that antenatal depression was significantly associated
with preterm birth (pooled RR: 1.13; 95% Confidence Interval (Cl): 1.06-1.21) and low
birth weight (pooled RR: 1.18; 95% Cl: 1.07-1.30). Antenatal depression was not
significantly associated with IUGR since only 2 out of 12 studies found this association.
Conversely, another meta-analysis performed by Grigoriadis et al. [37] assessed the
association between antenatal depression and adverse neonatal outcomes including
premature delivery, gestational age, birth weight, NICU admission, and Apgar scores at 1
and 5 minutes. They examined 30 prospective observational studies and found an
increased risk of premature delivery (OR: 1.37; 95% CI: 1.04-1.81) for depressed
mothers during pregnancy. Other adverse neonatal outcomes were not found to be
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significant. The postulated reasons for these discrepancies in results include the
heterogeneity of study design, specifically the different tools used to measure depression,
difference in the timing and severity of exposure, different confounding variables
controlled, and different sample populations and sizes.

2.2.6 Antenatal Depression: Child Developmental Outcomes
Antenatal depression has been found to be associated with poorer child
development including higher risk of cognitive delay [38-41], behavioural/social
problems [38, 42, 43], reduced emotional ability [41], and attention problems [44] even
after considering the confounding effects of other antenatal and postnatal risk factors. For
instance, a prospective cohort study (n=10,125) examined the association between
maternal depressive symptoms during pregnancy and child development at 18 months of
age found that persistent depression (EPDS ≥ 10 at 18 and 32 weeks of gestation) was
associated with developmental delay (OR: 1.34; 95% Cl: 1.11-16.2) for 18 month olds
when adjusted for smoking, maternal age, and life events [38]. The association remained
significant after adjustment for postnatal depression, although the effect was slightly
attenuated.
Furthermore, the effects of antenatal depression have been illustrated be a
predictor of violence [42] and depression [45] in adolescents. Pawlby et al. [45]
conducted a prospective longitudinal community-based study and followed 84% (n=127)
of the mother-child dyads from pregnancy to 16 years later. Psychological problems were
assessed for adolescents at 16-years-old using the Child and Adolescent Psychiatric
Assessment, in which 14% (18/127) were diagnosed with depressive disorder. The
adolescents exposed to antenatal depression (11/17) had a 4.7 times greater odds (95%
Cl: 1.60-13.86) of suffering from depression compared to youths not exposed. However,
this effect was mediated by cumulative exposure to maternal depression during the
lifetime of the child.
To add to this, antenatal depression is a strong predictor of postpartum depression
[21]. It is well-documented in the literature that postpartum depression has a negative
effect on mother-infant bonding and subsequent child development [46]. Hence, there are
difficulties in examining the individual effect of antenatal depression on long-term child
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development and adjusting for postnatal depression given that postnatal depression may
be an intermediate in the causal pathway or a standalone factor influencing child
development [38]. With that said, the effect of antenatal depression on child development
is substantial and estimated to explain 10-15% of the poor emotional and behavioural
outcomes in children [47].
2.3 Use of Selective Serotonin Reuptake Inhibitors (SSRIs) during Pregnancy:
Characteristics and Consequences
2.3.1 Treatments of Antenatal Depression
Given the potential negative consequences of antenatal depression on the wellbeing of the mother-child dyad, it is important that women with depressive symptoms
during pregnancy seek treatment. Antenatal depression can be treated or managed with
two main modalities: depression-specific psychotherapy and pharmacotherapy. For
pregnant women who are not suicidal and drug naïve (new to treatment for the illness)
with mild to moderate symptoms of depression, interpersonal psychotherapy is
recommended as initial treatment [48, 49]. For pregnant women who are suicidal or with
moderate to severe depression and have past history of good response to medication,
pharmacotherapy is recommended, specifically SSRIs, as the first line treatment, and is
often supplemented with psychotherapy [49].
Other classes of antidepressant prescribed during pregnancy are: serotoninnorepinephrine

reuptake

inhibitors

(SNRIs),

norepinephrine-dopamine

reuptake

inhibitors (NDRIs), serotonin antagonist and reuptake inhibitors (SARIs), and tricyclic
antidepressants (TCAs). In a large Québec study of 97,680 database subjects, Ramos et
al. [50] found that SSRIs (64.4%), SNRIs (12.3%), and TCAs (12.1%) were the three
most commonly used classes of antidepressants during pregnancy.

2.3.2 SSRIs
Currently the most prescribed class of antidepressants during pregnancy is SSRIs,
second-generation antidepressants [48, 50]. Although the first-generation antidepressants
such as TCAs are as effective in managing depressive symptoms as SSRIs, firstgeneration antidepressants have a high adverse effect profile and narrower therapeutic-
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toxicity window with common side effects of hypotension, sedation, and other
anticholinergic effects [51]. Additionally, unlike TCAs, SSRI overdose does not cause
cardiotoxicity and overdose-related death is rare [51]. However, there remain side effects
that accompany SSRI use, such are nausea, headache, sexual dysfunction, weight gain,
serotonin syndrome (headache, sweating, tremor), and increased risk of suicide in some
(within the first to second month of treatment, especially noted in youth and young
adults) [52]. There are currently six SSRIs available on the market in Canada: citalopram
(Celexa), escitalopram (Lexapro), fluoxetine (Prozac), fluvoxamine (Luvox), paroxetine
(Paxil), and sertraline (Zoloft) [51], all of which are approved for MDD treatment, except
for fluvoxamine, which is only approved for obsessive compulsive disorder [53].
Clinicians also prescribe SSRIs for other approved or unlabeled therapeutic uses other
than MDD, including anxiety disorder, obsessive-compulsive disorder, panic disorder,
social phobia, post-traumatic stress disorder, premenstrual dysphoric disorder, and eating
disorder [54].
Although as a class, various SSRIs share the basic mechanism of action, the
chemical structures of different types of SSRIs are considerably distinct. Consequently,
the pharmacokinetics properties, including absorption, distribution, metabolism, and
elimination of the medications are quite dissimilar [55]. Hence, the dosages administrated
and half-lives, which range from days to hours, are distinctive. For example, the half-life
of norfluoxetine, active metabolite of fluoxetine, is 7 days, so patients who abruptly
discontinue fluoxetine are less likely to suffer from discontinuation syndrome [55]. In
addition, specific SSRIs are metabolized by different hepatic cytochrome P450 enzymes
(CYPs) therefore blood concentration of metabolites highly depends on interindividual
variability [55].
The main mechanism of action of SSRIs is via inhibition of the neuronal 5hydroxytryptamine (5-HT) reuptake pump at the serotonergic synapse without affecting
other neuroreceptors [55, 56]. SSRIs decrease the efficiency of the serotonin reuptake
pump by 60% to 80%, thereby increasing the concentration of serotonin (5hydroxtryptamine, 5-HT) at the synaptic gap, and further enhancing serotongeric
neurotransmission [56]. Serotonin is known as the neurotransmitter associated with
complex emotions, such as affection and happiness [57]. However, the serotonin-
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deficiency syndrome offers a simplistic explanation for the complex pathology of
depression. The alternative theory explains the root cause of depression as due to the
deficiency of synaptogenesis and neurogenesis. An indirect effect of SSRIs activate the
signal transduction pathway on serotonergic neurons, which causes an increase
expression of regulatory factors such as Brain Derived Neurotropic Factor (BDNF) [58].
The functions of BDNF are to promote 5-HT neuron and synapse growth, differentiation,
and survival [58]. Overall, a concrete theory on the pathology of depression has yet to be
settled and the exact mechanisms of action of SSRIs are still under investigation.

2.3.3 Characteristics of SSRI Use during Pregnancy
It is estimated that 7% to 13% of pregnant women in the United States (US) use
SSRIs [59] and approximately 2.3% of 4 million infants born in the US each year are
exposed to in utero SSRIs according to the data from National Birth Defects Prevention
Registry [60]. Also, the rate of SSRIs use during pregnancy has increased over past
decade in North America [61] For example, in British Columbia, Canada, SSRI use
during pregnancy doubled from 2.3% to 5% between 1998 and 2001 [6].
Ramos et al. [50] discovered that the prevalence rate of antidepressant use
decreased significantly from 6.6% during the 12 months before the first day of gestation
to 3.7% in the first trimester. This decreasing trend continues to the second (1.6%) and
third trimester (1.1%) then significantly increases again to 7% during the 12 months after
the end of pregnancy. Their results suggest that pregnant women are hesitant to continue
treatment during pregnancy or healthcare providers are cautious about prescribing
antidepressants during pregnancy. Pregnant women who discontinue antidepressant
treatment are at an increased risk of relapse and withdrawal symptoms [14], which as
aforementioned has negative consequences for the mother and fetus.
Ramos et al. [50] also found several predictors of antidepressant use on the first
day and the end of pregnancy, which were advanced maternal age, recipient of welfare,
having a higher number of prescription medications, a higher number of prescribers, a
higher number of visits to physicians before pregnancy, and a depression diagnosis
before or during pregnancy. These predictors suggest that women who initiated or opted
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to continue antidepressant treatment during pregnancy were likely to have more severe
depressive symptoms compared to women who did not initiate or discontinued.
According to the Food and Drug Administration (FDA), all SSRIs, except
paroxetine, are classified as Pregnancy Category C drugs, meaning the risk is not ruled
out given the lack of sufficient and well-controlled human studies to support animal
studies that have produced evidences of adverse effect on the fetus [1, 61]. Paroxetine is
labeled as Pregnancy Category D drug, which means there is positive evidence of fetal
risk from human studies, specifically cardiovascular malformations [1, 61]. However, the
potential benefits of both Categories C and D drugs may permit their use during
pregnancy even with their potential risks [61].

2.3.4 Adverse Neonatal Outcomes of SSRI Use during Pregnancy
SSRIs are known to cross the human placenta so there are concerns over the
impact of their use during pregnancy on fetal development and health [62]. In addition,
the use of SSRIs during pregnancy remains controversial due to inconsistent results
regarding the risks of their use on several adverse neonatal outcomes. For instance, SSRI
usage late in pregnancy is known to be linked to a small increase in the risk of two
adverse neonatal effects: neonatal abstinence syndrome (NAS) and persistent pulmonary
hypertension (PPHN), although there are conflicting reports. Similarly, the finding for
other adverse neonatal outcomes such as preterm birth, SGA, Apgar score at 1 and 5
minutes, and NICU admission have been inconsistent in the literature.

2.3.4.1 Neonatal Abstinence Syndrome (NAS)
NAS or poor neonatal adaptation syndrome (PNAS) has been linked to exposure
to SSRIs in the late third trimester and is characterized by a list of signs and behaviours
that include irritability, abnormal crying, tremour, respiratory distress, digestive
disturbance, hypoglycemia, hypothermia, hyperreflexia, sleep disturbance, feeding issues,
and seizures [63]. These signs and behaviours are usually self-limiting and abate within a
few days to 2 weeks with strategies such as decreasing sensory stimulus and ensuring
skin-to-skin contact between mother and infant [64]. Neonates with severe NAS require
further monitoring and nursing in the NICU [65]. The pathophysiology of NAS is thought
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be caused by the serotonergic withdrawal effect or overstimulation of serotonergic
system from in utero SSRI exposure [63].
In a cohort study, Levinson-Castiel et al. [66] used the Finnegan score to assess
NAS of 120 term infants. Of the 60 infants exposed to in utero SSRIs, 18 (30%) showed
mild to severe symptoms of NAS whereas all non-exposed infants had normal Finnegan
scores. In a review, Moses-Kolko et al. [64] calculated the risk ratio (RR) and 95% CI
from the raw data of 5 cohort studies that examined the relationship between antenatal
SSRI exposure and NAS and found that late SSRI exposure was associated with an
increased risk (RR: 3.0; 95% CI: 2.0-4.4) of neonatal abstinence syndrome compared to
early SSRI and no SSRI exposure. Consequently, these infants were admitted to special
care nursery units (RR: 2.6; 95% CI: 1.4-4.7) and the hospital lengths of stay were
longer. Furthermore, a meta-analysis [67] of 12 studies, which aggregated to 3780 infants
exposed to antidepressants, found in utero antidepressants exposure was associated with
NAS (OR: 5.07; 95% CI: 3.25-7.90), respiratory distress (OR: 2.20; 95% CI: 1.81-2.66),
and tremours (OR: 7.89; 95% CI: 3.33-18.73)
Therefore the literature on the effect of late SSRI exposure on NAS has been quite
consistent. The FDA has issued a warning for physicians and mothers to be aware the risk
of NAS if taking antidepressants late in pregnancy, especially paroxetine due to its short
half-life [65].

2.3.4.2 Persistent Pulmonary Hypertension (PPHN)
PPHN occurs when the pulmonary vascular resistance or blood pressure remains
elevated after birth in newborns. This causes blood circulation to shunt from the right to
the left side of the circulatory system (away from the lungs), resulting in hypoxemia [68].
PPHN is estimated to occur in 1 or 2 infants per 1000 live births and is associated with
increased rate of mortality (10-20% even after treatment) and morbidity [68]. Due to
compromised tissue oxygenation, survivors have increased risk of cognitive delay,
hearing loss, and neurological abnormalities [69]. The findings on the relationship
between SSRI exposure and PPHN have been inconsistent where some studies have
found in utero SSRI exposure increases the risk of PPHN [68, 70-72], while others have
not [73, 74].
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A multinational population-based study [71] of over 1.6 million infants
discovered that newborns whose mothers filled a prescription for SSRIs later than 20th
week of gestation had a high risk of PPHN (adjusted OR: 2.1; 95% CI: 1.5-30). The
absolute risk of PPHN was 2.9 per 1000 live births for SSRI-exposed infants versus 1.2
per 1000 live births for infants not exposed. A recent meta-analysis [72] of seven high
quality studies showed that late pregnancy exposure to SSRIs was associated with PPHN
(OR: 2.50; 95% CI: 1.32-4.73), but not early pregnancy exposure to SSRIs. Clinically
speaking, the absolute risk of PPHN after late pregnancy SSRI exposure remained small
at 2.9 to 3.5 per 1000 live births since it is a rare disease. In 2011, the FDA revised their
warning and recommended that physicians continue their standard practice, as the
findings are still inconclusive [65].

2.3.4.3 Preterm Birth
Preterm birth is defined as the birth of the neonate at less than 37 weeks of
pregnancy [7] and continues to be one of the leading causes of neonatal and infant
mortality and morbidity in developed nations [75]. Approximately 75% of perinatal
mortality occurs in premature infants [75]. Additionally, premature infants are at higher
risk of having neonatal complications and chronic health problems [75].
Findings on the relationship between in utero SSRI exposure and preterm birth
have been inconsistent, as some studies have found evidence of a significant association
between in utero SSRI exposure and preterm birth [5, 7, 8, 76-80] whereas others have
not [63, 81, 82]. A retrospective cohort study of 33,791 mother-child pairs was conducted
by Grzeskowiak et al. [7] to investigate the neonatal outcomes of infants exposed to in
utero SSRIs during late gestation. They found that infants exposed to SSRIs during
pregnancy had an increased risk of preterm delivery compared to infants whose mothers
had psychiatric illness but no SSRI use (adjusted OR: 2.68; 95% CI: 1.83-3.93) and
compared to infants whose mothers had no psychiatric illness at all (adjusted OR: 2.46;
95% CI: 1.75-3.50). A meta-analysis of 14 studies documented that antidepressant use
during pregnancy was significantly associated with an increased risk of preterm birth
(pooled OR: 1.55; 95% CI: 1.38-1.74) [80]. However, the clinical significance is
questionable given the gestational age of neonates exposed to in utero SSRIs was three
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days shorter than non-exposed neonates. A comparison of depressed women who took
antidepressants during pregnancy versus depressed women who did not take
antidepressants during pregnancy in five studies showed a marginal trend toward
significance (pooled OR: 1.58; 95% CI: 0.97-2.56) suggesting that the effect of
antidepressant use on preterm birth is perhaps independent of maternal depression [80]
Moreover, underlying maternal depression may be a significant confounding
factor in the observed association between antenatal SSRI exposure and preterm birth. A
prospective observational study (n=2,793) found an increased risk of preterm birth among
women who took SSRIs during pregnancy with (OR: 2.1; 95% CI: 1-4.6) or without (OR:
1.6; 95% CI: 1.0-2.5) a major depressive episode. However, untreated women with a
major depressive episode did not have increased risk of preterm birth [83]. After
controlling for illness severity factors (age of illness onset, number of hospitalizations,
number of depressive episodes, and suicidal ideation.), the effect of antenatal SSRI
exposure on preterm birth was attenuated and no longer significant.

2.3.4.4 Apgar Score
Apgar score is a method used to assess the health of the newborn immediately
after birth to determine whether the newborn requires immediate medical care [84]. It is
based on five criteria: appearance/complexion (cyanosis, acrocyanosis, or no cyanosis),
pulse rate (absent, <100 beats/minute, or >100 beats/minute), reflex irritability grimace
(no response to stimulus, grimace on stimulus, or cry on stimulus), activity (no flexion,
some flexion, or arms and legs resistance), and respiratory effort (no cry, weak gasping,
or strong cry). The overall score is out of 10 with each criterion scored from 0 to 2 [84].
A score of 7 or higher is considered normal and 3 and below is critically low. The
assessment is usually administrated at one and five minutes after birth and repeated if the
score remains low. A low score at the one-minute test may indicate the newborn needs
further medical attention but typically the score improves with subsequent Apgar
calculations. If the score persists to be severely low at 10, 15, or 30 minutes, it is taken as
an indication that the newborn may suffer from neurological problems in the long run
[84].
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Many studies have documented the relationship between in utero SSRI exposure
and low Apgar scores [8, 76, 78, 85]. In a prospective cohort study, Lund et al. [8]
compared neonatal outcomes among 329 pregnant mothers exposed to SSRI treatment,
4902 pregnant women who had a history of psychiatric illness but no SSRI exposure, and
51,770 pregnant women with no psychiatric history. Infants exposed to in utero SSRIs
had an increased risk of scoring 7 or below for the 5-minute Apgar compared to infants
whose mothers had a history of psychiatric illness (adjusted OR: 6.58; 95% CI: 3.3912.74), and to infants whose mothers had no history of psychiatric illness (adjusted OR:
6.58; 95% CI: 3.39-12.74).

2.3.4.5 Neonatal Intensive Care Unit (NICU)
Several studies have documented that newborns exposed to in utero SSRIs are at
an increased risk of admission to NICU [6-8, 63]. A potential explanation is that neonates
exposed to in utero SSRIs have higher risk of developing NAS. Lund et al. [8] reported a
higher rate of NICU admission among newborns exposed to SSRIs in utero compared to
newborns whose mothers did not have a history of psychiatric illness (adjusted OR: 2.39;
95% CI: 1.69-3.39) and to newborns whose mothers did have a psychiatric history
(adjusted OR: 2.04; 95% CI: 1.42-2.94). Comparable results with similar adjusted OR
and 95% CI was reported by Grzeskowiak et al. [7]. Furthermore, a meta-analysis of 9
studies designed to investigate the relationship between late pregnancy SSRI exposure
and NAS reported that late pregnancy exposure to SSRIs is associated with an increased
risk of NICU admissions (OR: 3.3; 95% CI: 1.45-7.54) [63]. In contrast, Suri et al. [86]
did not find an increase in NICU admission in infants exposed to in utero SSRIs.

2.3.4.6 Small-for-Gestational Age (SGA)
SGA is defined as birth weight less than the 10th percentile for gestational age [7].
Of newborns who are defined as SGA, 70% are just constitutionally small and not at risk
of neonatal complications [87]. SGA in newborns who are not constitutionally small are
likely intrauterine growth restricted (IUGR) as a result of reduced oxygen and nutrient
supply to the fetus due to genetic or environmental factors [7]. Consequently, the fetus is
unable to reach its genetically programed potential growth. In addition, SGA in infants
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with birth weight lower than the 3rd percentile for gestational age typically have severe
IUGR, which can lead to neonatal complications including impaired thermoregulation,
hypoglycemia, polycythemia, impaired immune system, and increased risk of mortality
(4 to 8 times higher risk of mortality) [88]. Infants born SGA are also at increased risk of
having health problems later in life such as psychiatric disorders [89], cardiovascular
disease [90], and metabolic syndrome [90]. Thus far, the majority of studies have only
examined birth weight without accounting for gestational age so infants categorized as
low birth weight (<2500g) may include those of low gestation with appropriate birth
weight for their gestational age. Risk factors associated with SGA and IUGR can be
categorized into 3 classifications: maternal, fetal, and placental. Maternal factors include
vasculopathy disorders (preeclampsia, nephropathy), virus infections, maternal substance
abuse (smoking, alcohol use, illicit drug use), and other maternal demographic variables
(race, age, and parity) [91]. Fetal factors involve genetic abnormalities and major
congenital anomalies of the fetus. Lastly, placental factors include abnormal placental
blood circulation and chronic placental inflammatory lesions [92].
Some studies have found an association between in utero SSRI exposure and
SGA [6, 89] while others have not [7, 78, 85]. Oberlander et al. [6] used population
health data to link records of neonatal birth outcomes with maternal health and antenatal
SSRI prescription records and identified 1,451 depressed mothers treated with SSRIs,
14,234 depressed mothers without treatment, and 92,192 controls. They discovered that
birth weight and gestational age were significantly lower for neonates exposed to SSRIs
compared to neonates exposed to antenatal depression, but birth weight at less than 10th
percentile for gestational age was not significant. When propensity score matching was
used to control for severity of maternal illness, SSRI-exposed infants had a significantly
increased incidence of birth weight below the 10th percentile.

2.3.4.7 Large-for-Gestational Age (LGA)
LGA is defined as birth weight greater than 90th percentile for the gestational age
[93]. From the US birth registry, infants born at 40 weeks gestational age at 90th
percentile and 97th percentile have birth weight greater than 4000 grams and greater than
4400 grams, respectively [94]. Infants weighing 4000 grams and beyond are diagnosed as
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macrosomia and the morbidity, neonatal, and delivery (e.g. shoulder dystocia)
complication rates increase at this threshold [93, 95]. Infants born LGA are also at risk
for the development of Type II Diabetes Mellitus and metabolic syndrome later in life
[95]. The incidence of macrosomia has increased in developed countries as maternal age,
weight, and incidence of gestational diabetes at the time of pregnancy has increased and
the prevalence of smoking decreased [95]. The maternal risk factors associated with
excessive intrauterine growth are factors that cause excess delivery of nutrients to the
fetus including maternal diabetes, maternal pre-pregnancy weight, and excess gestational
weight gain [96]. Other risk factors are multiparity, advanced maternal age, post-term
pregnancy, previous LGA birth, genetic syndromes, race and ethnicity [96].
SSRI use has been found to be associated with weight gain (via stimulation of
appetite) [97], insulin resistance [98], diabetes [99], and obesity [100] therefore SSRI use
during pregnancy may indirectly influence LGA. Kallen et al. [78] used the Swedish
Medical Birth Registry to identify and prospectively collect a sample of over half a
million infants. Infants exposed to in utero SSRIs had an increased risk of being LGA
compared to total population group after adjusting for confounders, but which did not
reach statistical significance. The same result was found 6 years later in their follow-up
study [85].

2.3.5 Child Developmental Outcomes of SSRI Use during Pregnancy
Studies on the long-term development of children exposed to in utero SSRIs are
relatively limited compared to studies that examined adverse neonatal effects of SSRI
exposure. Our literature review identified 26 observational studies that investigated the
long-term child development outcomes of children born to mothers who took SSRIs
during pregnancy: 14 prospective [9-11, 101-111], 6 retrospective [12, 13, 112-115], and
6 case-control studies [116-121]. The age of the children involved in these studies ranges
from infants (6-months-old) to adolescence (17-years-old in a case-control study on
autism) with the majority of studies focused on children less than 6 years of age.
Different studies implemented different developmental tests to measure a wide range of
developmental outcomes. For example, for cognitive testing, the Bayley Scales of Infant
Development, Wechsler Preschool and Primary Scale of Intelligence, or McCarthy Scales
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were implemented by different studies. The sample size ranged from 22 children
(prospective study) to 8,833 children (population-based register study) exposed to in
utero SSRIs. The majority of the prospective studies had very small sample sizes. For
instance, a sample cohort from British Columbia, Canada was followed longitudinally
and examined in 3 different studies had an exposure group of ≤ 33 children [105-107].
The main developmental outcomes studied were organized into cognitive functioning,
fine motor movement, gross motor movement, personal/social behavioural development,
communication/language development, autism spectrum disorder (ASD), and attention
deficit hyperactivity disorder (ADHD).

2.3.5.1 Role of Serotonin
As mentioned previously, SSRIs increase the serotonin availability in the neural
network and are known to cross the placenta to the fetus [62]. In the early stages of
embryogenesis, serotonin is one of the main signaling molecules vital for fetal
neurodevelopment due to its importance in neuronal cell proliferation, migration,
signaling, synaptogenesis, and ultimately development of the CNS [122]. Therefore,
increased levels of serotonin during the crucial period of embryogenesis and fetal brain
development may have adverse consequences. In animal models, the early administration
of SSRIs in neonates and the subsequent increase in neural serotonin level have been
found to influence fetal brain development, as seen in changes in neuronal structure of
the somatosensory cortex and the related behavioural changes in adolescent rats [123]
(See Appendix A for animal model literature review).
Changes in serum protein levels integral for fetal neurodevelopment, such as
Activing A and Reelin gene expression, have been found linked to in utero SSRI
exposure in human studies [124, 125]. Additionally, serotonin is responsible for various
physiological pathways and has an extensive role in the CNS involving cognition,
memory, learning, and muscle tone [126].

2.3.5.2 Cognition/Problem Solving
No studies to date have found an association between in utero SSRI exposure and
adverse cognitive outcomes [9, 101-104, 121] in children. A prospective study conducted
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by Nulman et al. [9] recruited participants through the Motherisk Program and selected
four different study groups: depressed women on Venlafaxine (SNRI) during pregnancy
(n=62), depressed women on SSRIs during pregnancy (n=62), depressed women who
were untreated (n=54), and healthy women (n=62). They reported that the children (3 to
6-years-old) of healthy mothers had a significantly higher verbal and full scale IQ scores
(measured by Wechsler Preschool and Primary Scale of Intelligence) than children whose
mothers were on Venlafaxine and SSRIs while pregnant. However, by performing the
regression analysis and accounting for confounders, maternal IQ was discovered to be a
significant predictor for the child’s IQ. The difference found in verbal and full scale IQ
between the children exposed to in utero SSRIs and children of healthy mothers was
accounted for by maternal IQ and child’s gender and not by drug exposure.

2.3.5.3 Fine and Gross Motor Movements
Many studies have found an association between antenatal SSRI exposure and a
deficiency in fine [103] and gross [12, 103, 104, 109] motor movement in children.
Casper et al. [103] found that children (6 to 40-months-old) exposed to in utero SSRIs
had significantly lower scores on the Bayley Psychomotor Developmental Index (scoring
motor skills such as rolling, crawling, grasp, and use of utensils) and the Bayley
Behavioural Rating Scales, specifically on fine motor movement and tremulousness subscores. However, the study was underpowered with 31 children exposed to in utero
SSRIs and 13 children in the control group. In a similar study [104], children with longer
in utero exposure to SSRIs had an increased risk of having lower scores on the
Psychomotor Developmental Index compared to controls. However, results from
subsequent neurological examination discovered that the motor functioning of children
remained within the normal range.
A large population study [12] investigated the effect of antenatal SSRI exposure
on normal milestone development at 6 and 19 months of age. Using the Danish National
Birth Cohort database, a sample size of 81,946 was obtained and divided into 3 study
groups: women on antidepressant during pregnancy (n=415), depressed women without
antidepressant treatment (n=489), and non-depressed women (n=81,042). They found
that at the sixth-month developmental milestone evaluation, children who were exposed
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to SSRIs during the second and third trimesters had increased odds (adjusted OR: 2.1;
95% CI: 1.23-3.60) of abnormal gross motor development, specifically sitting without
support, compared to children of untreated mothers. However, this developmental delay
was within normal range of development and resolved by 19 months of age.

2.3.5.4 Communication/ Language Development
A Norwegian population-based prospective pregnancy cohort study [111] of
45,266 mothers with 51,748 children examined the language competency of 3-year-old
children using the language grammar rating scale questionnaire. They reported that
women with long-term SSRI use during pregnancy were more likely to have children
with lower language competency compared to children whose mother did not take SSRIs
during pregnancy. The underlying maternal anxiety and depression before and during
pregnancy were independent of the observed moderate language delay. Whether the
moderate language delay manifests later in the child’s life is unclear.
Other than the above study by Skurtveit et al. [111], no other studies to date has
found

an

association

between

in

utero

SSRI

exposure

and

delayed

communication/language development [101, 102, 109, 115].

2.3.5.5 Personal/Social Behavioural Development
Majority of studies did not indicate an association between antenatal SSRI
exposure and personal/social behavioural problems in children [9, 10, 13, 101, 102, 106,
107]; however, a few did [12, 104, 108, 110]. Casper et al. [104] found that longer
antenatal exposure to SSRIs (throughout pregnancy) significantly increased the risk of
lower Behavioural Rating Scale scores in 12-to-40-month-old children, particularly on
orientation/engagement and emotional regulation (p=0.007). However, based on a
subsequent neurological examination, mental development of children was found to be
normal. Pedersen et al. [12] reported that children exposed to SSRIs in the second or
third trimester had attention problems, specifically an inability to occupy themselves for
15 minutes, at the 19th month milestone evaluation compared to children whose mother
had untreated depression (OR: 2.1; 95% CI: 1.09-4.02) after adjusting for several
covariates including postnatal depression. Another study longitudinally followed 30
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children who developed SSRI-induced NAS and 52 children without NAS at the age of 2
to 6 years [108]. They discovered that children with NAS had normal cognitive ability
and developmental scores but were at an increased risk for abnormal social-behavioral
development (OR: 3.03; 95% CI: 1.07-8.60) compared to 52 children without NAS [108].
In another small sample study, Hanley et al. [110] found that children exposed to in utero
SSRIs had higher levels of internalizing behaviour (withdrawal, anxiety, depression) at
three and six years of age compared to non-exposed children independent of maternal
status of mood disorders throughout pregnancy and childhood.
Misri et al. [107] and Oberlander et al. [106] assessed internalizing (emotional
reactivity, withdrawal, irritability, depression, or anxiety) and externalizing (activity,
attention, and impulsivity) behaviors, respectively, in four and five year olds who were
and were not exposed to SSRIs antenatally. The level of internalizing behaviour was not
different between the children in the exposed and non-exposed groups. Instead, maternal
depression and anxiety were associated with an increase of internalizing behavior of their
children [107]. Antenatal SSRI and depression exposure did not predict externalizing
behaviours; on the other hand, current maternal mood and stress did [106]. In a follow-up
study, Oberlander et al. [105] explored the effect of antenatal SSRI exposure on
behavioural development of three-year-olds using Child Behavior Checklist. They found
that antenatal exposure to SSRIs in combination with concurrent maternal anxiety were
associated with an increased rate of internalizing behaviour. Externalizing behavior was
associated with current maternal mood but not antenatal SSRI exposure.
2.3.5.6 Autism Spectrum Disorder (ASD) and Attention Deficit Hyperactivity
Disorder (ADHD)
The evidence for an association between in utero SSRI exposure and ASD in
children has been inconsistent where some studies supported a positive association [114,
116, 117, 127] and some did not [113, 118, 119]. All the studies used health care
databases to select their sample, with sample sizes ranging from 812 to 654,288. A metaanalysis [128] of 4 case-control studies [116-119] supports the association between in
utero SSRI exposure and ASD (adjusted OR: 1.81; 95% CI: 1.47-2.24). However, the
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causality is unknown. Furthermore, the two population cohort studies [113, 114] from the
same database produced contradictory results.
Figueroa et al. [112] found that in utero exposure to SSRIs was not associated
with ADHD using claims-based data. However, a recent large database case-control
study [120] supported an association between antenatal antidepressant exposure and
ADHD after controlling for maternal depression (OR: 1.81; 95% CI: 1.22-2.70).

2.3.5.7 Covariates
Studies examined in this review of literature have controlled a variety of
confounders, including maternal age [12, 13, 104, 108], maternal IQ [9, 101, 102],
socioeconomic status [9, 101, 102], education [102, 103, 106], household income [9,
110], parity [7, 10], weight gain in pregnancy [101, 102], alcohol or tobacco use during
pregnancy [101, 102], severity and duration of depressive [101, 106, 107] and anxiety
symptoms [102, 105, 107], duration of treatment [106], presence of postpartum
depression [12, 102, 105], Apgar score [105], perinatal complications [112],
breastfeeding status [12], and other maternal medical factors (maternal diabetes,
hypertension, asthma, and thyroid disorder) [7, 103, 104]. A conceptual model based on
causality and temporality was constructed from the most commonly used confounders
and is shown in Appendix B. The model framed the objectives for this study.

2.3.5.8 Summary of Long-Term Developmental Studies
Some studies indicated that antenatal SSRI use could lead to adverse
developmental outcomes; however, the clinical relevance of such findings and their
manifestation later in life remain unclear. In all, the results of numerous studies seem to
suggest that antenatal SSRI usage does not have a serious detrimental impact on longterm development of children. However, due to the heterogeneity of study design,
difference in sample population and size, variation in confounder adjustment, and
different SSRI usage, it is very difficult to compare results and draw a definite
conclusion.
To date only a few studies have compared long-term outcomes of children of
depressed mothers, with or without SSRI usage during pregnancy, to non-depressed
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mothers during pregnancy [9-13]. These studies, therefore, were able to compare the
impact of maternal mood on child development and directly relate this to the effects of
antenatal SSRI exposure. The remaining studies had women who were not depressed
during pregnancy and were not using SSRIs as a control group, precluding the separation
of depression and SSRIs in their outcomes. Therefore, more well-designed studies are
needed to determine with certainty the long-term effects of antenatal SSRI exposure on
offspring.
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Chapter 3: Methods
3.1 Secondary Data Source: The Prenatal Health Project
This thesis project used data from a longitudinal cohort study, the Prenatal Health
Project (PHP). The PHP was designed to understand how prenatal factors impact the
health and wellbeing of mothers and children before and after pregnancy.
Pregnant women residing in the London-Middlesex, Canada region were
recruited, via convenience sampling, in ultrasound clinics in London, Ontario, Canada
between the periods of 2002 to 2005. Only women 16 years of age and older who carried
singleton pregnancies between 10 to 22 weeks gestation, spoke English, and lived in
London-Middlesex region were eligible. Exclusion criteria were high-risk pregnancy and
known congenital abnormalities. Data were collected throughout the three project phases:
prenatal, perinatal, and toddler/childhood phase, as described below.
PHP data collection was approved by the Ethics Review Broad for Health Science
Research Involving Human Subjects at the University of Western Ontario. The review
numbers of ethics approval are 08253E and 10787E.

3.1.1 Prenatal Phase
Women were initially informed about the PHP by ultrasound technicians at their
scheduled ultrasound appointments. Informed written consent and contact information
were gathered from women who were interested in participating after speaking with the
PHP research assistant. Participants were then contacted on the day of the scheduled
telephone interview to complete the prenatal survey (Appendix C). A trained interviewer
collected information on socio-demographics factors, maternal lifestyle, dietary intake,
and medical health. The variables of interest to this thesis are described in more detail in
Section 3.4.

3.1.2 Perinatal Phase
Consent for review of perinatal hospital medical records, including delivery room
charts and maternal and neonatal medical records, had been obtained at recruitment. Data
on obstetrical risk factors, delivery process and complications, and neonatal health status
and measurements were abstracted by a trained medical records technician using a Data
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Abstraction Form. The perinatal variables of interest to this thesis are also discussed in
detail in Sections 3.4.

3.1.3 Toddler/Childhood Phase
Women who were recruited at the start of the PHP were contacted again after
their child was between two to five years of age. Data regarding the mother’s and her
child’s psychosocial, developmental and nutritional health, and health system use were
collected over a scripted telephone interview. After completing the postnatal survey,
mothers were asked to participate in a short survey regarding the child’s development. If
mothers were interested in participating, the Ages and Stages Questionnaire (ASQ) was
mailed to the participating mothers. Mothers had the options of submitting the ASQ via
mail, online website, or over the telephone. Again, specific variables of interest will be
discussed in Section 3.4.
3.2 Prenatal Health Project Cohort
The recruitment flow chart is summarized in Figure 3.1. Initially, 3656 women
were asked to take part in the study and 2761 women agreed to participate. Of those
women who agreed, 2421 completed the prenatal survey via telephone interview for a
response rate of 66%. Women with a miscarriage, abortion, neonatal demise, or had
missing perinatal data were eliminated from the study (n=23). Additionally, 15 women
were lost to follow-up. Also, 26 women completed the survey twice for different
pregnancies; therefore one of the duplicates were chosen at random and excluded from
the sample. Overall, the PHP cohort consisted of 2357 women for whom both the
prenatal survey data and perinatal chart data were complete.
At the toddler/childhood phase when the children were two to five-years-old,
1608 (68%) participants from the original sample participated in the follow-up survey.
An aspect of the data collection at this phase included completion of a mailed Ages and
Stages Questionnaire (ASQ). Of those women who participated in the follow-up survey,
980 (61%) returned the completed ASQ.
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3.3 Study Groups
The study groups were identified based on the following prenatal variables:
prescription medication questions; and the 20-item Centre for Epidemiological Studies
Depression Scale (CES-D) score.
The Antidepressant group included mothers who were taking antidepressants
during pregnancy. Antidepressant use during pregnancy was collected during the prenatal
telephone survey by asking women to list the prescription medications they took
regularly at the time. Information on the amount (number of pills and dosage) and the
frequency of antidepressant use was also available. All antidepressants (SSRIs, SNRIs,
NDRIs, SARIs, and TCAs) reported were of interest for this thesis due to their shared
mechanism of action in inhibiting neurotransmitter (serotonin, norephinephrine, and
dopamine) reuptake at the synapse cleft to prolongs the neurotransmission [51]. The
selective serotonin reuptake inhibitors (SSRIs) class of antidepressants was especially of
interest since it is currently the most commonly prescribed and used class of
antidepressants during pregnancy [59] therefore it was further classified as its own
subgroup. In brief, women who reported taking antidepressants during pregnancy
belonged in the Antidepressant group with a subset in the SSRI subgroup.
The Depressive Symptoms group included mothers with depressive symptoms but
not taking antidepressants. Maternal depressive symptoms were assessed using the 20item CES-D score from the prenatal survey. The CES-D is a commonly used screening
instrument for depressive symptomology associated with major clinical depression in the
general population [27] and its use is recommended for the initial evaluation of antenatal
depressive symptoms [25]. The 20 items inquire how often (<1 day, 1-2 days, 3-4 days,
or 5-7 days) the participant felt a certain way (feeling of guilt, worthlessness, loss of
appetite) in the past week with each answer scored on a 4-point Likert scale ranging from
0 to 3. CES-D scores range from zero to sixty and the higher scores indicate greater
depressive mood. The cutoff point for possible clinical depression is ≥16 [27]. Therefore,
women who scored 16 or higher on the CES-D but did not take antidepressants belonged
in the Depressive Symptoms group.
Lastly, the Reference group consisted of women who did not take antidepressants
during pregnancy and scored lower than 16 on the CES-D.
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During the postnatal period, specifically when the toddler was >24 months,
mothers were asked “have you ever been diagnosed as having depression or a mood
disorder?” Previously diagnosed depression or mood disorder was dichotomized to yes or
no. To confirm the study group classifications, a cross tabulation was performed between
this variable and the study groups to compare the frequency distribution.
3.4 Variables of Interest
The following section of the thesis lists and describes in detail the applicable PHP
variables established a priori based on literature. Table 3.1 describes the variables on
maternal characteristics, details on coding, the original questions asked in the survey, and
when the variables were collected. Additionally, neonatal outcome variables gathered
during the perinatal phase are described in detail in Section 3.4.4 and Table 3.2.
Furthermore, Section 3.4.5 describes the developmental outcome measure, specifically,
Ages and Stages Questionnaire
3.4.1 Baseline Maternal Variables
Maternal Age
Participants self-reported their date of birth during the prenatal telephone survey.
Maternal age at the time of delivery was calculated by subtraction from delivery date.
The maternal age variable was kept continuous.

Parity
Parity was measured by asking women the year of each previous pregnancy and
whether it was a livebirth, stillbirth, or miscarriage/abortion. Parity was defined as the
number of times a woman has given live birth excluding stillbirth, miscarriages, and fetal
demises and dichotomized as 0 (nulliparous) or ≥1 (primiparous/multiparous) at the time
of the current pregnancy.

Education
Women reported their highest level of education as: elementary school, some high
school, completed high school, some college or university, college diplomas, university
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degree, trade school, or other (specified). Education was dichotomized to less
than/completed high school or greater than high school education. Less than high school
and completed high school were grouped together due to small cell sizes.

Income
Income was ascertained by asking women their best estimate of total gross
income (monetary value in CAN$) from all members of the household before taxes and
deductions in the past year. Women had the initial option of selecting <$30K or ≥$30K
then subsequent selection further divides into eight other total gross income amount
options ranging from <$10,000 to >$80,000. No income, don’t know, refuse to answer
were also available options and were coded as missing.
Income was then categorized as <30K (low-income), 30K-80K (middle-income),
and >80K (upper-middle-income). This categorization is based on a Statistics Canada
report on low-income-cut-off for urban community size of 100,000 to 499,999 in 2005,
which was $27,386 and $33,251 before taxes for family household of three and four
persons, respectively [129]. Conveniently, the cutoff given in the questionnaire was
consistent with the Statistics Canada cutoff for low-income families.

Marital Status
Women reported their current marital status as: married, common law (or living
as married), single/never married, separated/divorced, and widowed. Marital Status was
then

categorized

as

married,

common

law,

and

other

(single/never

married/separated/divorced) in the study. There were no widows in the cohort.

Pre-Pregnancy Body Mass Index
Body mass index (BMI) was calculated from the participant’s self-reported height
and weight and was calculated in kg/m2. Women were asked how tall they were without
shoes and how much they weighed before pregnancy. The standardized cutoff points
were categorized based on the current WHO categories: <18.5 (underweight); 18.5 to <25
(normal); 25 to <30 (overweight); and ≥30 (obese) [130]. Underweight and normal
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weight were grouped together due to the small cell size of underweight category in the
Antidepressant group.
3.4.2 Prenatal Maternal Variables
Alcohol use
Alcohol use during pregnancy was recorded by asking women the number of
drinks (i.e. glass of wine, beer, or mixed drink) they consumed typically per week at the
time. The detrimental effects of alcohol consumption during pregnancy are well
documented and there are no known safe level and time of alcohol consumption during
pregnancy. Therefore, alcohol usage during pregnancy was dichotomized as yes or no.

Smoking status
Women were asked “how many cigarettes do you typically smoke each day
now?” Like alcohol use, there are no safe levels and time of smoking during pregnancy
so smoking status during pregnancy was categorized as smoker during pregnancy and
non-smoker during pregnancy.

State Anxiety
State anxiety quantifies how anxious a person is feeling at a particular moment
and is measured using the 12-item shortened state version of the State-Trait Anxiety
Inventory (STAI) [131]. The STAI is one of the most widely researched and administered
tests for general anxiety. Women were asked how they were feeling in the past week
regarding their state of anxiety with questions such as “I am calm” and “I am jittery”.
Responses were recorded using the 4-point Likert scale ranging from 1 to 4: not at all,
somewhat, moderately so, and very much so. The STAI is a validated and reliable
screening tool for state anxiety and the higher score indicates higher level of state anxiety
[131]. Since there are no known cutoffs for STAI scores, the scores were kept continuous
and converted to standardized score for analysis.
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Medical Conditions
Women were asked whether or not they currently have or had any of the
following health conditions: heart disease/cardiovascular disease, high blood pressure
before pregnancy, high blood pressure during pregnancy, diabetes before pregnancy,
diabetes during pregnancy, asthma, and/or thyroid conditions. Medical conditions of
interest for this thesis were hypertension before and during pregnancy, diabetes before
and during pregnancy, asthma, and thyroid conditions. Each medical conditions of
interest was dichotomized as yes or no.

Weight Gain during Pregnancy
Weight gain during pregnancy was collected during the perinatal phase from the
Data Abstraction Forms under summary information on the additional maternal risk
factors during pregnancy. The underlying data source, the perinatal chart, only classifies
weight gain as: low ( ≤ 20lbs), appropriate (21lbs to 39lbs), and high weight gain
(≥40lbs).
3.4.4 Neonatal Outcome Variables
Preterm birth
Gestational age was obtained and calculated from the following data sources:
participant’s self-reported last menstrual period during the prenatal survey and newborn’s
date of birth; participant’s self-reported gestational period during the ultrasound clinic
visit and newborn’s date of birth; and infant’s delivery chart (gestational age recorded at
the time of delivery by medical experts). Gestational age from infant’s hospital chart was
deemed as the final and correct estimation if the gestational ages from the three data
sources were within seven days of each other. However, when an estimate from a data
source was discordant from the other estimates by more than seven days, then all
available hospital records were reviewed by a medical records technician to investigate
the possibilities of transcription error. In the case that the estimates were truly different
by more than 7 days, an OB/GYN reviewed all the hospital charts of the participant and
determined the best and final gestational age estimate. Gestational age was rounded to the
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following week if the days were ≥5. Preterm birth is defined as the birth of the baby at
less than 37 week; therefore it was dichotomized as <37 weeks and ≥37 weeks [7].

Size for Gestational Age
Size for gestational age was categorized as small-for-gestational age (birth weight
≤10th percentile for gestational age), average for gestational age (birth weight >10th to
90th percentile for gestational age) and large-for-gestational age (birth weight >90th
percentile for gestational age). The variables required to calculate size for gestational age
were newborn birth weight, gender, and gestational age. The method for this calculation
is based on Canadian population standards from Kramer et al. [132].
Apgar Score
Apgar scores taken at one (Apgar-1) and five (Apgar-5) minutes after birth were
abstracted from the infant’s hospital chart by trained technicians onto the Data
Abstraction Form during the perinatal stage. Apgar score assesses the following criteria
of the newborn: appearance/complexion, pulse rate, reflex irritability/grimace, activity,
and respiratory effort. Each criterion is scored from 0 to 2, with the overall score ranging
from 0 to 10. A score of 7 or higher is considered normal therefore Apgar score was
dichotomized as <7 and ≥7 [84].

Transferred to Specialized Care (TSC)
Infants transferred to specialized care (TSC) involved those admitted to Pediatric
critical care unit (PCCU) and neonatal intensive care unit (NICU) after birth. TSC was
dichotomized to whether newborns were transferred to PCCU/NICU or not.
3.4.5 Developmental Outcome Variables
Toddler/child development was examined using the age specific ASQ
administrated by the parents. ASQ is a developmental screening tool that evaluates five
domains: communication, gross motor, fine motor, problem solving, and personal social
skills [133]. Each domain has six items pertaining various domain-specific tasks such as
sentence formation, running, and drawing. The responses for each item are categorized as
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yes, sometimes, or not yet, each worth ten, five, and zero points, respectively. The
maximum score for each domain is sixty.
Conventionally, the score from each domain is compared to an age specific cutoff point. According to the ASQ manual, a child is considered a “fail” on the ASQ if the
child scored below but near the cutoff point for just one domain [133]. However, for the
purpose of this thesis project, the scores from each domain were kept continuous and
analyzed separately.
Missing items were handled according to the ASQ manual where missing items
were imputated with the average score for the specific domain [133]. Parents who
completed fewer than three items for each domain were removed from the sample. Out of
the 980 women who returned the ASQ, three ASQs were removed because one ASQ
could not be linked to the mother’s Study ID, one did not answer any questions, and
another only answered one question per domain. In addition, 67 toddlers/children were
preterm infants and were excluded, resulting in 910 toddlers/children analyzed for this
thesis.
3.6 Statistical Analysis
3.6.1 Preliminary Inspection and Handling of Dataset
Preliminary inspection of the dataset was executed using exploratory univariate
analysis to inspect the variables’ distribution, missing variables, and to ensure all relevant
variables were cleaned and made sense. Categories of variables with low observed
frequencies were collapsed together. After the subsequent data cleaning, variables were
recoded to the desired and intended use described in previous sections.

3.6.2 Descriptive Analysis: Objective 1
To describe the baseline characteristics of mothers who belonged in the
Antidepressant, SSRI, Depressive Symptoms, and Reference group for Objective 1, cross
tabulation analysis was used for categorical variables to report the frequency distribution
of maternal characteristics described in Section 3.4.1 and 3.4.2. Continuous variables
were compared among the study groups using descriptive analysis.
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3.6.3 Descriptive Analysis: Objective 2
To compare neonatal outcomes among the study groups for Objective 2, bivariable cross tabulation analysis was used again to examine the frequency distribution of
preterm delivery, small-for-gestational age (SGA), large-for-gestational age (LGA),
Apgar score, and TSC. Due to the imbalanced dataset of the study groups and the small
sample size of the Antidepressants group and SSRI subgroup, the Morbidity Ratio (MR)
methodology of Liddell [134] was used to obtain a 95% confidence interval of the rate
ratio for a Poisson estimate. The MR was the ratio of morbidity (preterm and LGA)
observed to those expected morbidity rate. The expected morbidity rate was based on
some reference population, in this case, the Reference group and the Depressive
Symptoms group.
The analysis of Apgar scores and TSC were restricted to only infants born at term
to eliminate the potential of confounding by preterm birth. To calculate the expected
morbidity rate of the remaining neonatal outcomes (Apgar-1, Apgar-5, and TSC) for the
MR, the reference population was based only on the Depressive Symptoms group due to
the low frequency count of adverse events and the similar rates of neonatal outcomes
among the Reference group and Depressive Symptoms group.
The two assumptions made were the Observed Counts (O) follows a Poisson
distribution (random variable with a Poisson distribution) and Expected Counts (E) were
error-free because it is based on a sufficiently large sample [134]. The linked relationship
between the Poisson and Chi-square distribution allowed us to use the Chi-square
distribution to get the critical value to calculate the confidence limits. The following
equations were used to calculate the lower and upper limits of the 95% confidence
interval [134].
1

Lower limit: find 𝜒2L for which Q(𝜒2L∣2O) = 1 – 2α;
1

1

then E L = 2 𝜒2L and MR L = 2 𝜒2L/E;
1

Upper limit: find 𝜒2U for which Q(𝜒2U∣2O+2) = 2α;
1

1

then E U = 2 𝜒2U and MR U = 2 𝜒2 U/E
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3.6.4 Descriptive Analyses: Objective 3
The ASQ score for each domain was negatively skewed with a ceiling effect due
to the normal development of the vast majority of toddlers and children. Therefore to
compare the long-term child development outcomes (communication, fine motor
movement, gross motor movement, problem solving, and social/personal skills) of
toddlers, preschool age children among the study groups for Objective 3, bootstrapping
method was used where observations from the original datasets were resampled 2000
times with replacement for each study group’s domains to construct a normal
distribution. The 95% confidence interval for each study group of each domain was
calculated from the mean values of the bootstrapped samples using the Bias Corrected
and accelerated (BCa) method. The BCa method adjusts for the bias in the bootstrap
estimates using the bias correction and acceleration coefficients hence it is considered the
improved bootstrap confidence interval [135]. The SAS macro Jackboot was downloaded
from the SAS website in order to run the bootstrap [136].

3.6.5 Secondary Analyses
The small sample size of the Antidepressant group prevented an adequate
multivariable analysis for the investigation of the increased frequency of LGA observed
in the Antidepressant group. To investigate whether this increased frequency was related
to antidepressant use or the maternal characteristics of those taking antidepressants, a
multivariable analysis of the Reference group was performed. The Reference group was
chosen as a proxy population for the Antidepressant group due to the substantially larger
sample size and the similar maternal baseline characteristics between the two groups.
Missing cases for LGA were deleted and missing variables were handled using listwise
deletion.
Univariable analysis, specifically Pearson chi-square or Fishers exact test was
performed to examine the relationship between the individual categorical covariates and
LGA. The crude relationships between the individual covariates and LGA were examined
using simple logistic regression. Variables with significance level of p≤0.2 were fitted in
the multivariable logistic regression model. The backward elimination procedure was
used with the pre-set significant level of p<0.05. The model included maternal education,
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income, pre-pregnancy BMI, parity, smoking status during pregnancy, diabetes before
and during pregnancy, and weight gained during pregnancy. Alcohol use during
pregnancy was not included in the model due to low cell count. Statistical analyses were
performed using SAS 9.4.
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Figure 3.1. Prenatal Health Project Recruitment Flow Chart

Table 3.1. Variable definitions of maternal characteristics
Maternal
Characteristics
Variables
Smoking Status

Alcohol Use

Parity –
Previous live births
(excluding
stillbirths,
miscarriages, and
fetal demises)
Education –
Highest education
level

Original Question Asked
in PHP Questionnaire

Original Format of Variable

Variable Codes

How many cigarettes do
you typically smoke each
day now?

Numeric Value

0 = Non-smoking
during pregnancy (0)

How many drinks do you
typically have per week
now? By drink I mean a
glass of wine, beer, or a
mixed drink

Numeric Value

Please tell me the year that
each of your previous
pregnancies ended, and if it
was a livebirth, stillbirth,
miscarriage, or abortion.

Numeric Value (1 to 8)

What is your highest level
of formal education you
have completed?

1=Elementary School
2=Some high school
3=Completed high school
4= Some college or university
5=College diploma
6=University degree
7=Trade school
8=Other

1 = Smoked during
pregnancy (≥ 1)
0 = Non-consumer
during pregnancy (0)
1= Consumer during
pregnancy (≥ 1)
0 = 0 live births
1 ≥ 1 live births

0 = Did not complete
high school or
Completed high school

When the Variable
was Acquired
(Phase)
Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)
Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)

Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)

Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)

1 = More than high
school
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Income –
Total household
income

Marital Status

Maternal Age

Best estimate of total gross
income from all member of
the household before taxes
and deductions in the past
year
What is your best estimate
of the total income of all
members of your household
from all sources before
taxes and deductions for the
past year? By total income I
mean total gross income
from paid employment,
government assistance,
student loans, or
inheritance.
What is your current
marital status?

What is your date of birth?

1 = less than 30K
2 = greater than or equal to 30K
3 = less than 15K
4 = greater than or equal to 15K
5 = less than 60K
6 = greater than equal to 60K
7 = less than 10K
8 = 10K to $14,900
9 = 15K to 19,999
10 = 20K to 29,999
11 = 30K to 39,999
12 = 40K to 59,999
13 = 60K to 79,999
14 = 80K or more
15 = no income
16 = don’t know
17 = refused to answer
1=Married
2=Common Law
3=Single/Never married
4=Separated/divorced
5=Widowed
Women’s’ date of birth

1 = less than 30k
2 = 30k-80k
3 = more than 80K

Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)

Refused to
answer/unclear coded
as missing

1 = Married
2 = Common Law
3 = Single/Never
married,
Separated/divorced
Continuous

Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)
Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)
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Maternal prepregnancy BMI

How tall are you without
shoes?

Numeric Variable then
calculated to BMI (kg/m2)

How much did you weigh
prior to this pregnancy

Weight gain during
pregnancy

Antidepressant Use

Depressive
Symptoms

Anxiety Measure

Other risk factors during
pregnancy: Other

Please tell me any OTC and
prescription medications
you take regularly now, the
number of pills or dosage if
you know it, and how many
times you take them per
day
20-items CES-D
questionnaire

12 items shorten state
version of the State-Trait
Anxiety Inventory (STAI)

1 = <18.5
(underweight), 18.5<25 (normal)

Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)

2 = 25-<30
(overweight)

0=20lbs or less
1=appropriate
2=40lbs or more
Comes from Pregnancy risk
factors in perinatal data set
(s3_orisk1_details and
s3_orisk2_details)
List of medications

3 = ≥30 (obese)
0 = 20lbs or less
1 = appropriate
2 = 40lbs or more

0 = none
1 = Antidepressants

Numeric Variable

0 = less than 16

Numeric Variable

1= equal or greater than
16
Continuous

After birth; Data
extracted from the
hospital medical
records
(Perinatal Phase)

Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)

Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)
Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)
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Diagnosed with
Depression or Mood
Disorder in the Past

Have you ever been
diagnosed as having
depression or a mood
disorder?

Yes or No

Dichotomized

≥24 months old
follow up
questionnaire
(Postnatal Phase)

Medical Conditions

Pre-existing/Existing
Health Conditions

Yes or No:

Dichotomized

I am going to read a list of
health conditions. For each,
please say yes if you
currently have conditions or
have had the condition in
the past. If you do not have,
or have never had the
condition please respond
with no. Do you have or
have you ever had.

High blood pressure before
pregnancy

Telephone interview
after first visit to
ultrasound clinic
(Prenatal Phase)

Diabetes before pregnancy
Asthma
Thyroid condition
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Table 3.2. Variable definitions of neonatal outcomes
Neonatal
outcomes

Available in Dataset

Original Format
of Variable

Variable Codes

Preterm

Gestational Age:
1. Patient’s self-reported
LMP and baby’s date of birth

Dichotomous

0 = term birth
1 = preterm birth

2. Gestational age at reported at
delivery (expert’s medical opinion)

When the Variable
was Acquired
(Phase)
After birth; Data
extracted from the
hospital medical
records
(Perinatal Phase)

3. Patient’s self-reported gestational at
recruitment and baby’s date of birth

Size for
Gestational Age

Preterm Labour: <37 weeks
Gestational Age:
1. Patient’s self-reported
LMP and baby’s date of birth
2. Gestational age at reported at
delivery (expert’s medical opinion)
3. Patient’s self-reported gestational at
recruitment and baby’s date of birth

Numeric

0 = 3rd percentile (severe
SGA)/3rd to 10th percentile
(moderate SGA)
1 = 10th to 50th percentile
(AGA)/50th-90th percentile
(AGA)

After birth; Data
extracted from the
hospital medical
records
(Perinatal Phase)

2 = >90th percentile (LGA)

Infant Birth weight:
Grams, Lbs, Oz
Infant Gender:
Male or Female
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Apgar-1

Apgar Score Total

Numeric

1 = less than 7
2 = equal to or greater than 7

Apgar-5

Apgar Score Total

Numeric

1 = less than 7
2 = equal to or greater than 7

Transferred to
Specialized Care
(TSC)

Transferred to home, triage/7east, with
mother/well nursery, PCCU, NICU
triage, or NICU admission

Dichotomous

0 = not admitted to NICU
and PCCU
1 = admission to NICU and
PCCU

After birth; Data
extracted from the
hospital medical
records
(Perinatal Phase)
After birth; Data
extracted from the
hospital medical
records
(Perinatal Phase)
After birth; Data
extracted from the
hospital medical
records
(Perinatal Phase)
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Chapter 4: Results
4.1 Study Sample
As presented in Section 3.2, the initial PHP cohort consisted of 2357 women who
completed the cross sectional survey and consented to the release of perinatal birthing
information. Only women who completed the CES-D question and prescription drugs
questions were included for the study. Of the initial cohort, 16 women did not complete
CES-D Score, one woman did not complete the prescription drugs question, and another
woman did not complete either; therefore, 18 women were excluded, leaving the sample
size of 2339 women with both prenatal and perinatal information. Figure 4.1 shows the
sample size flow of the study groups in the Prenatal, Perinatal, and Postnatal Stages. The
sample size for each study group at the outset (prenatal) was as followed:


44 women (1.88%) reported antidepressant use during the pregnancy
(Antidepressant group);



32 women (1.37%) were on SSRIs (SSRI subgroup);



421 women (18.00%) reported clinically significant depressive symptoms
without antidepressant intervention (Depressive Symptoms groups);



1874 women (80.12%) did not have clinically significant depressive
symptoms nor report antidepressant use (Reference group).

4.2. Antidepressant Use
The specific antidepressants used during pregnancy are presented in Table 4.1. Of
the 44 women who reported antidepressant use during pregnancy, 32 (72.7%) were
SSRIs, five (11.4%) were SNRIs, four (9.1%) were on TCAs, two (4.6%) on NDRIs and
one (2.3%) on SARI. Further data on the amount and frequency of use is presented in
Table 4.2. The dose for all women was within the recommended range and two women
were on the maximum recommended dose: sertraline (SSRI) – 200mg/day and
nefazondone (SARI) – 600mg/day. All women reported having taken antidepressants
daily except for three women: one took venlafaxine (SNRI) every 2-3 days, one took
sertraline daily if she could afford it, and one took fluoxetine (SSRI) every other day.
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4.3 Characteristics of the Study Groups
Maternal characteristics are presented in Table 4.3, stratified by study group
membership. Given the imbalanced sample size distribution of the study groups and the
small sample size of the Antidepressants group and SSRI subgroup, we were left to
describe the maternal characteristics of the study groups by comparing frequency
distribution and means.
To begin, women in the Antidepressant group and SSRI subgroup were more
likely to be overweight or obese, where the Antidepressant group had the largest
percentage (30.2%) of overweight (BMI 25 - <30kg/m2) women before pregnancy and
the SSRI subgroup had the largest percentage (25%) of obese (BMI ≥30kg/m2) women
before pregnancy. The Antidepressant group and SSRI subgroup were also more likely to
be primiparous/multiparous (61.4% and 56.3%, respectively), whereas the percentages of
nulliparous and primiparous/multiparous for both Reference group and Depressive
Symptoms groups are close to equal at 50%.
Furthermore, women in the Antidepressant group and SSRI subgroup were older,
more likely to be married, more likely to have higher than a high school education, and
more affluent relative to women in the Depressive Symptoms group. Specifically, the
mean maternal age of women in the Antidepressant group and Depressive Symptoms
group were about 31 (standard deviation [SD] of 4.4) and 28 (standard deviation [SD] of
5.5), respectively. The rates of women who had an education higher than high school in
the Antidepressant group and SSRI subgroup were 86.4% and 84.4%, respectively,
compared to 67.7% of women in the Depressive Symptoms group.
The majority (75%) of women in the Antidepressant group and SSRI subgroup
were married compared to 56.4% in the Depressive Symptoms group. Women in the
Depressive Symptoms group were more likely to be single/never married, or
separated/divorced (20%) compared to other study groups (3.1% - 6.8%).
Women in the Antidepressant group and SSRI subgroup were also more affluent
such that 36.4% and 37.5% had an annual household income greater than $80,000
compared to 24.8% of women in the Depressive Symptoms group. Furthermore, women
in the Depressive Symptoms group were more likely to report an annual household
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income of less than $30,000 (25.6%) compared to the Antidepressant group (18.2%) and
SSRI subgroup (15.6%).
The demographic characteristics (maternal age, income, marital status, and
education) of women in the Antidepressant group and SSRI subgroup were comparable to
women in the Reference group. Women in the Reference group were the most affluent
and only 8.5% of women reported an annual household income of less than $30,000.
Notably, the women in the Depressive Symptoms group were more likely to
display high-risk behaviours during pregnancy. Women in the Depressive Symptoms
group had higher rate of smoking (22.5%) and alcohol consumption (4.5%) during
pregnancy compared to the other groups (smokers: 7.8%-11.4%; alcohol use: 1.8%3.1%). Furthermore, women in the Depressive Symptoms group were the most likely to
gain 40 pounds or more during pregnancy (15.7%) and the SSRI subgroup had the fewest
women gaining 40 pounds or more during (9.4%). Other than that, weight gain during
pregnancy was relatively comparable in all groups.
Very few women in the study gained 40lbs or more during pregnancy, had
hypertension, diabetes, and thyroid condition before and/or during pregnancy with cell
counts at ≤5 in the Antidepressant group and SSRI subgroup. Women in all study groups
had similar rates of hypertension before and/or pregnancy (9.3%-11.4%). Both the
Antidepressant group and SSRI subgroup were more likely to have a thyroid condition
(6.8% and 9.4%) and diabetes (4.5% and 6.3%); however, the cell sizes were too small to
make further inferences. The occurrence of asthma was more likely for women in the
Antidepressant group (25%) compared to other study groups. The mean (SD) state
anxiety STAI raw scores for the Antidepressant, SSRI, Depressive Symptoms, and
Reference group were 23.3 (7.2), 23.2 (7.0), 27.5 (5.5), and 19.4 (4.4), respectively.
For the confirmation of the classification of study groups, it was found that high
percentages (87.5% and 94.1%) of women in the Antidepressant group and SSRI
subgroup were diagnosed with depression or mood disorder in the past. Whereas 31.9%
and 11.7% of women in the Depressive Symptoms group and Reference group were
diagnosed with depression or mood disorder in the past.
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4.4 Study Groups and Outcomes
4.4.1 Neonatal Outcomes
The frequency distributions for preterm birth, SGA, and LGA are shown in Table
4.4a. The rate of preterm birth and LGA was higher in the Antidepressant group (preterm:
13.6%; LGA: 32.6%) and the SSRI subgroup (preterm: 18.8%; LGA: 32.3%) than the
Depressive Symptoms (preterm: 7.6%; LGA: 12.0%) and Reference group (preterm:
5.3%; LGA: 12.6%). SGA infants were not observed in the Antidepressant group and
SSRI subgroup.
Table 4.4b presents the expected count of preterm birth, SGA, and LGA (based on
the rate of the Reference group), the MR of observed/expected, and the 95% Poisson
confidence interval of the rate ratio. There was a significantly higher count of preterm
births in the SSRI subgroup when the expected rate was based on the rate of the
Reference group (MR=3.4, 95% CI: 1.3-7.7). The count of LGA was also significantly
higher in the Antidepressant group (MR=2.6, 95% CI: 1.4-4.4) and SSRI subgroup
(MR=2.6, 95% CI: 1.2-4.7). When using the rate based on the Depressive Symptoms
group, the number of LGA was significantly higher in both the Antidepressant (MR=2.6,
95% CI: 1.4-4.4) group and SSRI (MR=2.7, 95% CI: 1.3-5.0) subgroup as presented in
Table 4.4c.
The frequency distributions for Apgar-1, Apgar-5, and TSC of infants born at
term are shown in Table 4.5. Preterm newborns (n=138) were excluded; therefore, the
sample sizes of the study groups of infants born at term were reduced to: 38 in the
Antidepressant group, 26 in the SSRI subgroup, 389 in the Depressive Symptoms group,
and 1774 in the Reference group. The number of newborns in the Antidepressant group
and SSRI subgroup who were transferred to specialized care units and scored lower than
seven on the Apgar at one and five minutes were very diminutive at less than five
observations. However, infants in the Antidepressant group and SSRI subgroup were
more likely to score less than seven on the Apgar at one and five minutes relative to the
Depressive Symptoms and Reference group. The small cell sizes make it difficult to show
significant increased risks when the expected rate was based on Depressive Symptoms
group. The rates of TSC were comparatively similar for all the study groups.
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4.4.2 Developmental Outcomes
Table 4.6 presents the bootstrapped mean and the 95% Bootstrap Bias Corrected
and accelerated (BCa) Confidence Interval of the ASQ score for each domain. Due to
loss to follow up (n=749), unwillingness to participate in the ASQ survey (n=628),
removal of the returned incomplete ASQ survey (n=3), and the elimination of
toddler/children who were born preterm (n=67), the sample sizes of the study groups
were reduced to 15 in the Antidepressant group, 9 in the SSRI subgroup, 120 in the
Depressive Symptoms group, and 775 in the Reference group.
Toddlers/children of the Reference group and the Depressive Symptoms groups
had very similar bootstrapped mean scores and overlapping confidence intervals across
all domains.
The Antidepressant group had a lower bootstrapped mean score for the
communication (54.8; 95% CI: 49.2-58.6), gross motor (53.7; 95% CI: 45.2-58.9), fine
motor (49.9; 95% CI: 40.7-55.2), and personal/social skills (54.3; 95% CI: 49.3-58.3)
domain compared to the Depressive Symptoms and Reference groups. The SSRI
subgroup had the lowest bootstrapped mean score for the communication (52.4; 95% CI:
45.8-58.1), gross motor (49.4; 95% CI: 36.5-57.1), fine motor (44.4; 95% CI: 32.2-56.0),
and personal/social skills (52.2; 95% CI: 45.3-58.2) domains compared to all the groups.
Due to the small sample size of the Antidepressant group and SSRI subgroup, the 95%
Bootstrap Bias Corrected and accelerated (BCa) Confidence Intervals were very wide and
overlapped in all the study groups for all development domains and further analysis and
inference was not possible.
4.5 Secondary Analysis on the Reference Group
Given an increased frequency of LGA in the Antidepressant group, it was of
interest to investigate whether this increased frequency was due to the Antidepressant,
per se, or the maternal characteristics of those taking antidepressants. The small sample
sizes precluded a full multivariable analysis of this question. However, the role of various
covariates in the risk of LGA in the Reference group was investigated to explore
inferences related to maternal characteristics.
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Table 4.7 presents the frequency distribution and the univariable association
between maternal characteristics and LGA using Pearson chi-square test and Fisher exact
test. The sample size used for this analysis was 1854 after removing 20 missing cases
from the size of gestational age variable. The results of the univariable and multivariable
logistic regression analysis are shown in Table 4.8. The variables that had p≤0.2 in
univariable analysis, thus included in the multivariable logistic regression model, were:
education level, annual income, pre-pregnancy BMI, parity, smoking status during
pregnancy, diabetes before and/or during pregnancy, and weight gain during pregnancy.
Although alcohol use during pregnancy had a p-value of 0.1227, it was not included in
the model due to small cell size.
The final sample size of the multivariable logistic regression model was 1684.
The variables that stayed significantly associated (p<0.05) to LGA in the model were prepregnancy BMI, parity, smoking during pregnancy, diabetes before and/or during
pregnancy, and weight gained during pregnancy.
Compared to women whose pre-pregnancy BMI was <25 (normal or
underweight), women whose pre-pregnancy BMI was ≥30 (obese) had increased odds of
having infants born LGA (OR=2.05, 95% CI: 1.36-3.08). Women who had a prepregnancy BMI of 25 to <30 also had increased odds of having infants born LGA
(OR=1.58, 95% CI: 1.12-2.24) compared to the infants of women whose pre-pregnancy
BMI was <25 (normal or underweight).
Women who were primiparous or multiparous were more likely to have LGA
infants compared to women who were nulliparous (OR=1.51, 95% CI: 1.12-2.04).
Women who smoked during pregnancy were less likely to have LGA infants compared to
women who did not smoke during pregnancy (OR=0.47, 95% CI: 0.23-0.96).
Furthermore, women who had diabetes before and/or during pregnancy had an increased
risk of having LGA infants compared to women who did not have diabetes before and/or
during pregnancy (OR=2.79, 95% CI: 1.43-5.46).
Lastly, compared to women who had appropriate weight gain during pregnancy
(>20 to <40lbs), women who gained 40lbs or more had an increased risk of delivering
LGA infants (OR=2.23, 95% CI: 1.51-3.30).
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In the model diagnostic, the Hosmer and Lemeshow goodness-of-fit test showed
that the multivariable logistic regression model was a good fit (chisq: 3.15, df: 6,
p=0.7901). The pseudo R-square and max-rescaled pseudo R-square for the model were
0.0290 and 0.0544, respectively. The diagnostic test for multicollinearity indicated that it
was not a concern since all the predictor variables had variance inflation factor of lower
than two.
4.6 Summary of Findings
In regards to Objective 1, our findings suggested that women on antidepressants
were more likely to be overweight and obese before pregnancy, primiparous or
multiparous, and asthmatic in comparison to the other study groups. Furthermore, women
displaying depressive symptoms were younger, less likely to have more than high school
education, less likely to be married, less financially well-off, more likely to display
harmful behaviours during pregnancy, and had the highest STAI raw scores compared to
the other study groups.
In regards to Objective 2, the results from the univariable analysis suggested that
infants exposed to antidepressants and SSRIs in utero were more likely to be LGA
compared to the infants whose mothers belonged to the Depressive Symptoms or
Reference groups. Based on the multivariable logistic regression of the Reference group,
women who were primiparous/multiparous, overweight and obese before pregnancy,
diabetic before and/or during pregnancy, and had weight gain of 40lbs or more during
pregnancy had an increased odd of having LGA infants.
In regards to Objective 3, toddlers/preschoolers of women who were on SSRIs
had lowest mean score in the communication, fine and gross motor movement, and
personal/social skills domain of the ASQ compared to the other groups.
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Figure 4.1. Sample flow for the Prenatal, Perinatal, and Postnatal Phases: the Flow
Pertains to the Analyses for this Thesis Project.
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Table 4.1. Antenatal antidepressant use
Antidepressants (n=44)
SSRIs (n=32)
Citalopram (Celexa)
Fluvoxamine (Luvox)
Paroxetine (Paxil)
Sertraline (Zoloft)
Fluoxetine (Prozac)
Unknown
SNRIs (n=5)
Venlafaxine (Effexor)
NDRIs (n=2)
Bupropion (Wellbutrin)
Bupropion (Zyban)
SARIs (n=1)
Nefazodone (Serzone)
TCAs (n=4)
Amitriptyline

Frequency (%)
5 (11.4%)
1 (2.3%)
9 (20.4%)
9 (20.4%)
7 (15.9%)
1 (2.3%)
5 (11.4%)
1 (2.3%)
1 (2.3%)
1 (2.3%)
4 (9.1%)
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Table 4.2. Amount and frequency of antenatal antidepressant use
Antidepressants
SSRIs
Citalopram (Celexa)
Fluvoxamine (Luvox)
Paroxetine (Paxil)

Count – Amount/day

5 – 20mg/day
1 – 50mg/day
1 – 10mg/day
6 – 20mg/day
1 – 30mg/day
1 – 40mg/day
Sertraline (Zoloft) 1 – 25mg/day
1 – 50mg/day
5 – 100mg/day
2 – 200mg/day1
Fluoxetine (Prozac) 1 – 10mg every other day
2 – 20mg/day
3 – 40mg/day
1 – 60mg/day
Unknown 1 – 75mg/day

SNRIs
Venlafaxine (Effexor) 1 – 20mg every 2-3 days
2 – 75mg/day
1 – 150mg/day
1 – 250mg /day
NDRIs
Bupropion (Wellbutrin)
Bupropion (Zyban)
SARIs
Nefazodone (Serzone)
TCAs
Amitriptyline

1 – 150mg/day
1 – 2 tablets/day
1 – 600mg/day1

1 – 20mg/day
2 – 25mg/day
1 – 60mg/day
1
Maximum recommended dose
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Table 4.3 Maternal characteristics in the four study groups: exposed to any
antidepressant, exposed to SSRIs, exposed to maternal depressive symptoms without
antidepressant use, and unexposed to either depressive symptoms or antidepressants
(Total N=2339)
Maternal Characteristics

Baseline Maternal
Variables
Parity (n=2339)
0
≥1
Education Level (n=2339)
≤High School
>High School
Annual Income* (n=2189)
<30K
30K-80K
>80K
Marital Status* (n=2338)
Married
Common-law
Other
Pre-Pregnancy BMI*
(n=2251)
Underweight (<18.5) and
Normal (18.5 - <25)
Overweight (25 - <30)
Obese (≥30)

Antidepressant
Use
(n=44)

SSRI
Use
(n=32)

Depressive
Symptoms,
no
Antidepressant
Use (n=421)
Frequency (%)

Neither
Depressive
Symptoms nor
Antidepressant
Use (n=1874)

17 (38.6%)
27 (61.4%)

14 (43.8%)
18 (56.2%)

214 (50.8%)
207 (49.2%)

927 (49.5%)
947 (50.5%)

6 (13.6%)
38 (86.4%)

5 (15.6%)
27 (84.4%)

136 (32.3%)
285 (67.7%)

268 (14.3%)
1606 (85.7%)

8 (18.2%)
20 (45.4%)
16 (36.4%)

5 (15.6%)
15 (46.9%)
12 (37.50%)

95 (25.6%)
184 (49.6%)
92 (24.8%)
50 missing

150 (8.5%)
893 (50.3%)
731 (41.2%)
100 missing

33 (75.0%)
8 (18.2%)
3 (6.8%)

24 (75.0%)
7 (21.9%)
1 (3.1%)

237 (56.4%)
99 (23.6%)
84 (20.0%)
1 missing

1518 (81.0%)
259 (13.8%)
97 (5.2%)

21 (48.8%)
13 (30.2%)
9 (20.9%)
1 missing

17 (53.1%)
7 (21.9%)
8 (25.0%)

247 (62.5%)
82 (20.8%)
66 (16.7%)
26 missing
Mean (SD)
30.8 (4.3)
28.3 (5.5)
Frequency (%)

1197 (66.0%)
394 (21.7%)
222 (12.3%)
61 missing

5 (11.4%)

3 (9.4%)

1 (2.3%)

1 (3.1%)

5 (11.4%)

3 (9.4%)

94 (22.5%)
3 missing
19 (4.5%)
3 missing
44 (10.4%)

145 (7.8%)
19 missing
34 (1.8%)
20 missing
174 (9.3%)

2 (4.5%)

2 (6.3%)

18 (4.3%)

55 (2.9%)

78 (18.6%)
2 missing
15 (3.6%)

263 (14.1%)
7 missing
86 (4.6%)

Maternal Age (n=2339)
Prenatal Maternal
Variables
Smoked During
Pregnancy* (n=2317)
Alcohol Use During
Pregnancy* (n=2316)
Hypertension Before
and/or During Pregnancy
(n=2339)
Diabetes Before and/or
During Pregnancy
(n=2339)
Asthma (n=2330)*

31.0 (4.4)

11 (25.0%)

5 (15.6%)

Thyroid Condition
(n=2339)

3 (6.8%)

3 (9.4%)

30.3 (4.8)
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Diagnosed with
Depression or Mood
Disorder in the Past**
(n=1345)
Yes
No

21 (87.5%)
3 (12.5%)

16 (94.1%)
1 (5.9%)

Weight Gain during
Pregnancy (n=2339)
20lbs or less
Appropriate
40lbs or more

0
39 (88.6%)
5 (11.4%)

0
29 (90.62%)
3 (9.38%)

State Anxiety (STAI Raw
Score) (2337)

23.3 (7.2)

23.2 (7.0)

66 (31.9%)
141 (68.1%)

22 (5.22%)
333 (79.10%)
66 (15.68%)
Mean (SD)

27.5 (5.5)
1 missing
*Calculated percentage does not include missing observations
** Percentage based on postnatal data

130 (11.7%)
984 (88.3%)

68 (3.6%)
1592 (85.0%)
214 (11.4%)

19.4 (4.4)
1 missing

Table 4.4a Neonatal outcomes in the four study groups: exposed to any antidepressant, exposed to SSRIs, exposed to maternal
depressive symptoms without antidepressant use, and unexposed to either depressive symptoms or antidepressants (Total
N=2339)
Antidepressant
Use
(n = 44)

SSRI
Use
(n = 32)

Depressive Symptoms,
no
Antidepressant
Use (n = 421)
Frequency (%)

Neither Depressive Symptoms nor
Antidepressant
Use
(n = 1874)

Gestational Age
Preterm 6 (13.6%)
Size for Gestational Age*
SGA 0 (0)
LGA 14 (32.6%)
1 missing

6 (18.8%)

32 (7.6%)

100 (5.3%)

0 (0)
10 (32.3%)
1 missing

30 (7.2%)
50 (12.0%)
6 missing

126 (6.8%)
234 (12.6%)
20 missing

*Calculated percentage does not include missing observations

Table 4.4b The expected count in each study group (reference = unexposed to either depressive symptoms or antidepressants),
the ratio of observed/expected and the 95% Poisson confidence interval of the rate ratio of observed/expected
Antidepressant
Use

Preterm
LGA

SSRI
Use

expected number
2.3
1.7
observed/expected (CI) 2.6 (1.0, 5.7)
3.5 (1.3, 7.7)*
expected number
5.4
3.9
observed/expected (CI) 2.6 (1.4, 4.4)*
2.56 (1.2, 4.7)*
Note: expected is based on the rate in the No Depressive Symptoms/No Antidepressant group
*statistically significant

Depressive Symptoms,
no
Antidepressant
Use
22.5
1.42 (1.0, 2.0)
52.4
1.0 (0.7, 1.3)
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Table 4.4c The expected count in each study group (reference = exposed to depressive symptoms and unexposed to
antidepressants), the ratio of observed/expected and the 95% Poisson confidence interval of rate ratio of
observed/expected
Antidepressant
Use

SSRI
Use

Preterm

expected number
3.3
2.4
observed/expected (CI) 1.8 (0.7, 4.0)
2.5 (0.9, 5.4)
LGA
expected number
5.3
3.7
observed/expected (CI) 2.6 (1.4, 4.4)*
2.7 (1.3, 5.0)*
Note: expected is based on the rate in the Depressive Symptoms/No Antidepressant group
*statistically significant
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Table 4.5a Neonatal outcomes of term infants in the four study groups: exposed to any antidepressant, exposed to SSRIs,
exposed to maternal depressive symptoms without antidepressant use, and unexposed to either depressive symptoms or
antidepressants (Total N=2201)
Antidepressants
Use
(n = 38)

SSRI Use
(n = 26)

Depressive Symptoms,
no
Antidepressant
Use (n = 389)

Neither Depressive
Symptoms nor
Antidepressant
Use
(n = 1774)

Frequency (%)
Apgar-1* (n=2132)
<7
≥7
Apgar-5* (n=2132)
<7
≥7

4 (11.4%)
31 (88.6%)
3 missing

4 (17.4)
19 (82.6)
3 missing

24 (6.5)
346 (93.5)
19 missing

143 (8.3)
1584 (91.7)
47 missing

1 (2.9)
34 (97.1)
3 missing

1 (4.4)
22 (95.6)
3 missing

1 (0.3)
370 (99.7)
18 missing

8 (0.5)
1718 (99.5)
48 missing

2 (5.3)
36 (94.7)

1 (3.8)
25 (96.2)

13 (3.3)
376 (96.7)

42 (2.4)
1729 (97.6)
3 missing

TSC* (n=2198)
Yes
No

*Calculated percentage does not include missing observations
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Table 4.5b The expected count in each exposure group (reference = exposed to depressive symptoms and unexposed to
antidepressants), the ratio of observed/expected, and the 95% Poisson confidence interval of rate ratio of observed/expected
Antidepressant
Use

SSRI
Use

Apgar-1 <7

expected number
2.4
1.5
observed/expected (CI) 1.7 (0.5, 4.2)
2.7 (0.7, 6.9)
Apgar-5 <7
expected number
0.1
0.1
observed/expected (CI) 10.6 (0.3, 59.0)
16.1 (0.4, 89.7)
TSC
expected number
1.3
0.9
observed/expected (CI) 1.6 (0.2, 5.7)
1.15 (0.03, 6.4)
Note: expected is based on the rate in the Depressive Symptoms/No Antidepressant group
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Table 4.6 Mean and the 95% Bootstrap Bias Corrected and accelerated (BCa) Confidence Interval of ASQ Scores from five
domains of term toddlers in the four study groups: exposed to any antidepressant, exposed to SSRIs, exposed to maternal
depressive symptoms without antidepressant use, and unexposed to either depressive symptoms or antidepressants
(Total N=910)
ASQ Domains

Communication (n=909)
Gross Motor (n=909)
Fine Motor (n=906)
Problem Solving (n=908)
Personal/Social (n=908)

Antidepressants
(n = 15)

SSRIs
(n = 9)

Depressive
No Depressive
Symptoms/No
Symptoms (n = 775)
Treatment Exposure
(n = 120)
Bootstrap Mean (95% Bootstrap BCa Confidence Interval)
54.8 (49.2, 58.6)
52.4 (45.8, 58.1)
55.3 (53.6, 56.9)
56.0 (55.4, 56.5)
1 missing
53.7 (45.2, 58.9)
49.4 (36.5, 57.1)
55.2 (52.5, 56.9)
56.4 (55.8, 56.8)
1 missing
49.9 (40.7, 55.2)
44.4 (32.2, 56.0)
50.6 (47.8, 53.0)
51.4 (50.6, 52.3)
1 missing
3 missing
57.3 (47.0, 60.0)
56.7 (44.7, 60.0)
55.2 (53.0, 57.0)
55.0 (54.4, 55.5)
2 missing
54.3 (49.3, 58.3)
52.2 (45.3, 58.2)
55.5 (52.9, 57.0)
55.1 (54.5, 55.6)
2 missing
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Table 4.7 LGA frequency by maternal characteristics (n=1854)
Categorical Maternal
Characteristics
Education Level (n=1854)
≤High School
>High School
Annual Income (n=1755)
<30K
30K-80K
>80K
Marital Status (n=1854)
Married
Common-law
Other
Pre-Pregnancy BMI (n=1793)
Underweight (<18.5) and
Normal (18.5 - <25)
Overweight (25 - <30)
Obese
(≥30)
Parity (n=1854)
0
≥1
Smoked During Pregnancy
(n=1835)
Yes
No
Alcohol Use During Pregnancy
(n=1834)
Yes
No
Hypertension Before and/or
During Pregnancy (n=1848)
Yes
No
Diabetes Before and/or During
Pregnancy (n=1854)
Yes
No
Asthma (n=1847)
Yes
No
Thyroid Condition (n=1854)
Yes
No

LGA Frequency (%)

P-value

27/265 (10.2%)
207/1589 (13.0%)

0.1977a

15/148 (10.1%)
124/886 (14.0%)
82/721 (11.4%)

0.1854a

195/1502 (13.0%)
28/255 (11.0%)
11/97 (11.3%)

0.6235a

123/1184 (10.4%)
63/388 (16.2%)
40/221 (18.1%)

0.0003a

97/915 (10.6%)
137/939 (14.6%)

0.0097a

9/143 (6.3%)
223/1692 (13.2%)

0.0173a

1/34 (2.9%)
229/1800 (12.7%)

0.1138b

23/171 (13.4%)
210/1677 (12.5%)

0.7277a

16/53 (30.2%)
218/1801 (12.1%)

<.0001a

35/261 (13.4%)
197/1586 (12.4%)
8/84 (9.5%)
226/1770 (12.8%)

0.6551a
0.3816a
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Weight Gain during Pregnancy
(n=1854)
20lbs or less
Appropriate
40lbs or more
Numeric Maternal
Characteristics
State Anxiety (Standardized)
(1853)
Maternal Age (n=1854)
a

Pearson chi-square test
Fisher exact test
Note: significant level ≤0.2
b

6/66 (9.1%)
185/1575 (11.8%)
43/213 (20.2%)
LGA Frequency (%)
Mean (SD)
234 (12.6%)
0 (1)
234 (12.6%)
30.6 (4.7)

0.0016a

Non LGA Freq
(%)
Mean (SD)
1619 (87.4%)
0 (1)
1620 (87.4%)
30.3 (4.9)
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Table 4.8 Univariable and multivariable logistic regression of maternal characteristics
and LGA
Categorical Maternal
Characteristics

OR (95% Wald CI) [p-value]
Univariable

Education Level
≤High School
>High School
Annual Income
<30K
30K-80K
>80K
Marital Status
Married
Common-law
Other
Pre-Pregnancy BMI
Underweight (<18.5) and
Normal (18.5 - <25)
Overweight (25 - <30)
Obese (≥30)
Parity
0
≥1
Smoked During Pregnancy
Yes
No
Alcohol Use During Pregnancy
Yes
No
Hypertension Before and/or
During Pregnancy
Yes
No
Diabetes Before and/or During
Pregnancy
Yes
No
Asthma
Yes
No
Thyroid Condition
Yes
No
Weight Gain during Pregnancy
20lbs or less
Appropriate
40lbs or more

Multivariable (n=1684)
entered

0.76 (0.50, 1.16) [0.1992]
[reference]
0.88 (0.49, 1.57) [0.6637]
1.27 (0.94, 1.71) [0.1184]
[reference]

entered

[reference]
0.83 (0.54, 1.26) [0.3752]
0.86 (0.45, 1.64) [0.6401]

not entered

[reference]
1.67 (1.20, 2.32) [0.0021]
1.91 (1.29, 2.82) [0.0012]

[reference]
1.58 (1.12, 2.24) [0.0093]*
2.05 (1.36, 3.08) [0.0006]*

[reference]
1.44 (1.09, 1.90) [0.0100]

[reference]
1.51 (1.12, 2.04) [0.0072]*

0.44 (0.22, 0.88) [0.0205]
[reference]

0.47 (0.23, 0.96) [0.0376]*
[reference]

0.21 (0.03, 1.53) [0.1227]
[reference]

not entered

not entered
1.09 (0.68, 1.72) [0.7277]
[reference]

3.14 (1.72, 5.74) [0.0002]
[reference]

2.79 (1.43, 5.46) [0.0028]*
[reference]

1.09 (0.74, 1.61) [0.6552]
[reference]

not entered

0.72 (0.34, 1.51) [0.3843]
[reference]

not entered

0.75 (0.32, 1.76) [0.5113]
[reference]
1.90 (1.32, 2.76) [0.0006]

0.68 (0.28, 1.65) [0.3973]
[reference]
2.23 (1.51, 3.30) [<.0001]*
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State Anxiety (Standardized) 1.00 (0.87, 1.15) [0.9743] not entered
Maternal Age 1.02 (0.99, 1.05) [0.2534] not entered
*statistically significant level <0.05
Note: Alcohol use during pregnancy not entered into model due to small cell
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Chapter 5: Discussion
The purpose of this thesis study is to investigate the effects of maternal
antidepressant use, with special focus on SSRI use during pregnancy on neonatal and
long-term child developmental outcomes. Specifically, the first objective is to describe
the baseline characteristics of pregnant women who belonged in the following study
groups: those who took antidepressants during pregnancy (Antidepressant group); those
who took SSRIs during pregnancy (SSRIs subgroup); those who have elevated depressive
symptoms during pregnancy but not taking antidepressants (Depressive Symptoms
group); and those who do not have elevated depressive symptoms and do not take
antidepressants during pregnancy (Reference group). The second objective is to compare
the neonatal outcomes, specifically, preterm delivery, small-for-gestational age (SGA),
large-for-gestational age (LGA), Apgar scores at one and five minutes, and NICU
admission among newborns whose mothers belonged to the study groups. The third
objective is to compare the long-term development of toddlers and preschoolers whose
mothers belonged to the study groups. Due to the low prevalence of antidepressant use
during pregnancy, the issues of small cell sizes precluded the control for potential
confounding variables. This needs to be recognized beforehand, as it might have
impacted the findings. Nonetheless, this study had findings consistent with the current
literature concerning the use of antidepressants during pregnancy.
5.1 Discussion Pertaining to Objective 1: Study Group Baseline Characteristics
In regards to Objective 1, our findings from the descriptive analysis suggested
women in the Antidepressant group were more likely to have BMI greater than or equal
to 25 (overweight and obese) before pregnancy, were of higher parity, and more likely to
be asthmatic compared to women in the Depressive Symptoms and Reference group.
These findings support those of prior large Canadian population-based studies that
investigated the relationship between antidepressant use, depression, and obesity [137139]. Specifically in a 10-year longitudinal cohort study, Patten et al. [137] found an
association between obesity (BMI ≥30) and antidepressant use, particularly SSRIs and
Venlafaxine (SNRI), but not major depressive episodes after adjusting for covariates.
Their follow up study found that major depressive episodes and antidepressant use were
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both associated with significant but modest increase in BMI over time [138]. In contrast,
another Canadian cross sectional study reported a lack of association between depression
and overweight/obesity status however an elevated risk of obesity (BMI ≥ 30) was
observed among depressed women taking antidepressants, specifically TCAs [139].
Generally, there is a large body of literature supporting the association between
depression and obesity [140, 141]. Various comorbid conditions of depression, especially
atypical depression and obesity, have been suggested to operate bi-directionally through
interlinked psychological, behavioural, and biological (HPA-axis disruption) factors and
share common pathological pathways involving the inflammatory, metabolic, and
endocrine systems [140, 141]. Grundy et al. [139] suggest that, for those on
antidepressants, antidepressant use might have played a role as an intermediate between
the depression and obesity.
A plausible explanation for the observed association is the side effect of weight
gain related with antidepressant treatment. Evidence from the current literature and a
meta-analysis indicate that the antidepressants, amitriptyline (TCA) and paroxetine
(SSRI) are most consistently associated with clinically significant weight gain that could
lead to overweightness or obesity [97, 100, 142, 143]. Citalopram (SSRI) has been
reported on a fairly consistent basis to increase the risk of moderate weight gain over
long term use [100]. Other types of SSRIs (Fluvoxamine, Sertraline, and Fluoxetine) and
classes of antidepressants including bupropion (NDRI), venlafaxine (SNRI), and
nefazodone (SARI) used by the women in the Antidepressant group have generally been
found to be weight neutral and even weight loss promoting [100]. However, long term
use of the “weight neutral” SSRIs have been reported to be associated with slight weight
gain as well [143].
The proposed mechanisms underlying antidepressant induced weight gain are the
alternation of a highly complex and overlapping network of signaling molecules
including hormones (cortisol via HPA-axis), cytokines (leptin, tumor necrosis factor, etc),
and neurotransmitters (serotonin, norepinephrine, etc) involved in hunger, satiety, insulin
resistance, and overall metabolic homeostasis [97]. This manifests in an increase of
caloric intake due to food craving, reduction resting metabolic rate, and ultimately, the
promotion of the metabolic syndrome including obesity [97, 100]. Therefore the evidence
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provides a strong indication that the use of antidepressants in our population may have
played a role in the increased rate of high BMI (≥25) observed in the Antidepressant
group and SSRI subgroup.
During the postnatal (follow-up) survey, 87.5% and 94.1% of women in the
Antidepressant group and SSRI subgroup, respectively reported past diagnosis of
depression or mood disorder. Hence the underlying psychiatric illness may have been a
contributing risk factor for high BMI (overweightness and obesity) in the Antidepressant
group and SSRI subgroup. Confounding by prescriber expectancy might also partially
explain this result such that physicians prescribed SSRIs to women more susceptible to
weight gain [137].
Overall, given evidence provided in the literature and our results, we hypothesize
that the combined factors of antidepressant use and underlying psychiatric illness could
have affected the risk of overweight and obesity in our sample population and those
variables are all involved in a mutual causal pathway. However, it is worth mentioning
that we did not model the determinants of overweight and obesity in our data because it is
beyond the scope of this thesis.
Moreover, the association between overweightness/obesity and asthma might
explain the increased cases of asthma observed in women taking antidepressants. The
increased secretion of cytokine, specifically leptin from fat tissue commonly observed in
obesity is suggested to contribute in the pathology of asthma, a chronic inflammatory
disorder of the airways [144].
Women in the Antidepressant group and Reference group were similar in regards
to a number of characteristics including older age, married status, higher income and
education. This is partially consistent with the literature that report pregnant women on
antidepressants are more likely to be older [50, 145], have higher education (>12 years of
education) [145], be recipients of welfare [50], and more likely to consume alcohol and
smoke [145]. These high-risk behaviours during pregnancy were observed in women of
the Depressive Symptoms group, which could be related to their demographics of lower
education level, lower income, younger age, non-married status, and poorer mental health
compared to other groups. All those characteristics relating to disadvantages are
associated with higher risk of adverse lifestyle practices (concurrent alcohol and tobacco

67
use) during pregnancy [146] and are common risk factors of antenatal depression [29].
Furthermore, women in the Antidepressant group exhibited lower mean state anxiety
STAI raw score than women in the Depressive Symptoms group. This result was
expected given that depression and anxiety are frequent co-morbid conditions with
overlapping symptoms and antidepressants have an anti-anxiety effect, which reduces the
level of anxiety symptoms and elevates mood [146].
The findings that women with elevated depressive symptoms during pregnancy
were more likely to display harmful behaviours, have poorer mental health, and be
disadvantaged are consistent with the current literature [22, 23]. This result suggests that
women with these risk factors need to be readily recognized and require special attention
in primary obstetric care settings in order to target screening and treatment efforts.
However, many pregnant women with depressive symptoms are undertreated or not
treated during this vulnerable time [18, 23], which could be the case for the women in the
Depressive Symptoms group. Importantly, untreated depression during pregnancy can
persist into postpartum period [147].
5.2 Discussion Pertaining to Objective 2: Neonatal Outcomes
In regards to Objective 2, our univariable results indicated that infants exposed to
in utero antidepressants (Antidepressant group) were at significantly higher risk to be
LGA compared to the infants whose mothers belonged to the Depressive Symptoms and
Reference groups. Exposure to SSRIs in utero was also found to increase the risk of LGA
compared the Depressive Symptoms and Reference group. A previous observational
study reported an increased risk of LGA in women exposed to antidepressants during
pregnancy compared to the total population after adjusting for potential confounders
(year of birth, maternal age, parity, and smoking during pregnancy), although the
difference was not statistically significant [78]. The same result was found in their
follow-up study [85].
Given the small sample size of the Antidepressant group, an analysis at the
multivariable level was precluded, thus potential confounders were not accounted for.
Instead, the Reference group was analyzed to investigate the maternal characteristics in
relation to LGA. Our results from the multivariable logistic regression of the Reference
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group found that women who were primiparous/multiparous, overweight and obese
before pregnancy, diabetic before and/or during pregnancy, or had weight gain of 40lbs
or more were associated with an increased odds of having LGA infants, whereas smoking
during pregnancy was associated with decreased likelihood of having LGA infants. This
is consistent with previous literature [96, 148] and other analyses in this dataset citing
these maternal factors as strong predictors of delivering LGA infants [149]. Thus it is
possible that these maternal characteristics known to affect insulin resistance may offer
an explanation for the increased frequency of LGA in the Antidepressant group.
Although antidepressant use is not a known risk factor for delivering LGA
infants, observational studies have produced sufficient data indicating the association
between antidepressant use, particularly TCAs and SSRIs, and the risk factors pertaining
to LGA including insulin resistance [98], dyslipidemia [98, 150], diabetes [99, 151], and
as discussed above (Section 5.1), obesity [100]. Specifically, in a Norwegian general
community cross sectional study, overall SSRI use was found to be associated with
abdominal and general obesity, hypercholesterolemia, and an observed trend toward
diabetes [98]. A meta-analysis of 12 high quality observational studies concluded that
there was a significantly increased risk of type 2 diabetes mellitus among long-term users
of SSRIs and TCAs after adjusting for body weight, depression severity, and physical
activity [152]. Additionally, consistent data from the literature review suggested the use
of paroxetine increases the risk of dyslipidemia and glucose intolerance [100]. The
increased risk of diabetes among women in the Antidepressant group and SSRI subgroup
was not observed. As a result, it is assumed that their glucose tolerance, albeit not
considered in our study, might have been compromised to a certain degree given Grave et
al. [149] found abnormal glucose tolerance as a significant risk factor of LGA in this
dataset.
Generally, it is suspected that antidepressants increase serum cortisol level and
insulin resistance by altering the HPA axis [153]. Specifically, TCAs inhibit
noradrenaline reuptake transporters at the synapses increasing noradrenaline, which then
leads to a hyperglycemic effect [99]. Furthermore, some SSRIs have been found to
activate insulin receptor 1 kinases resulting in inhibition of insulin signaling and
induction of cellular insulin resistance [154]. Therefore we hypothesized that the
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antidepressant-induced hyperglycemic effect during pregnancy increases glucose
availability and delivery to the fetus resulting in fetal hyperinsulinemia and increases the
risk of LGA. Dyslipidemia in pregnant women has also been found to have a positive
influence on fetal growth due to increased serum lipid availability [155]. In addition, the
relationship between the risk of LGA and pre-pregnancy BMI is directly proportional and
independent of gestational diabetes in women with adequate gestational weight gain [96].
So in connection to Discussion section 5.1, the increased rate of high BMI (≥25) in the
Antidepressant group may be a main factor explaining the increased frequency of LGA
infants in this group. Overall, the mechanism of antidepressants induces unwanted side
effects that fit under the umbrella of metabolic syndrome and could have potentially
contributed to LGA in the Antidepressant group.
On the other hand, because antidepressant use occurs in the context of underlying
depression, the comorbid conditions of depression and obesity are worthy of discussion
since they share common pathological pathways such as increased level of proinflammatory cytokines, insulin resistance, and altered plasma glucose levels [156],
which could contribute to LGA as well.
Furthermore, infants exposed to antenatal SSRIs had an increased risk of being
preterm compared to infants of the Reference group. Results regarding the relationship
between antenatal SSRI exposure and premature birth have been inconsistent in the
literature [21, 79]. Evidence indicates that longer duration [76] and late trimester (2nd and
3rd) [157, 158] exposure of antenatal SSRIs is associated with preterm birth and other
adverse birth outcomes. We had limited information on the timing and duration of
antidepressant use in our database. Research has demonstrated that antidepressant use
decreases significantly once pregnancy is identified from the rate of 6.6% (12 months
before gestation) to 3.7% (first trimester) and continues to decrease to 1.6% (second
trimester) and 1.1% (third trimester) [50]. Most women in the Antidepressant group and
SSRI subgroup were in the second trimester (38 out of 44 and 29 out of 32) and the rest
in the first trimester at the time of the prenatal survey. Coupled with the fact that most
pregnant women take antidepressant for a prolonged period as maintenance therapy to
prevent recurrences of psychiatrics episodes [145], it is likely that majority of women
were adherent to the treatment throughout pregnancy and the difference in the timing and
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duration of exposure did not greatly affect our results. Furthermore, it is possible that the
increased risk of preterm birth observed in the SSRI subgroup may be confounded by the
underlying maternal depression.
Additionally, non-significant increases in the risk of low Apgar-1, Apgar-5, and
TSC were observed in infants exposed to in utero antidepressants. However, due to both
the exclusion of preterm infants and the sample size limitation, these adverse outcomes
were rare events with low frequency count for the Antidepressant group and SSRI
subgroup. Therefore we had low statistical power to detect significant differences.
5.3 Discussion Pertaining to Objective 3: Toddler/Child Development
In regards to Objective 3, our descriptive analysis found lower mean scores in the
communication, fine and gross motor movement, and personal/social skill domains of the
ASQ among toddlers and children whose mothers that belonged in the SSRI subgroup
during pregnancy in comparison to the other groups. The largest deficit was observed in
the fine and gross motor domains by a maximum difference margin of approximately 7
points between the SSRI subgroup versus both the Depressive Symptoms and Reference
group. Furthermore, consistent with all previous studies that investigated cognitive
development [9, 12, 101-104, 121], we did not observe a deficit in the mean score for the
problem-solving domain among toddlers and children in the SSRI subgroup. The
interpretation of our results warrants caution since the sample size was small and we were
unable to control for confounders. As a result, the clinical significance is not known.
Nonetheless, our preliminary findings are supported by several observational
studies that found a deficit in motor development among children exposed to antenatal
SSRIs. Specifically, a few small sized studies (31 to 51 exposed participants) reported an
association between SSRI use during pregnancy and significantly lower scores on the
Bayley Psychomotor Developmental Index particularly in the gross motor development
in two studies [104, 109] and in the fine motor and tremulousness sub-scores of the
Bayley Behavioural Rating Scales in another study [103]. However, Casper et al. [104]
reported normal range of motor development after the neurological exam. Additionally, a
large cohort-based Danish population study [12] found that 6 month old children who
were exposed to SSRIs during second and third trimester had increased odds of delayed
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gross motor development, specifically sitting without support compared to children of
untreated mothers even after adjusting for covariates including postnatal symptoms of
depression. Again, the motor development milestones were within the normal expected
range and the gross motor delays were resolved at the age of 19 months. Other studies
have also reported a transient motor delay in the infancy and early toddlerhood (1-1.5
years) stages that later resolves past approximately 1.5 years of age [11, 121]. The
authors of these studies suggested in utero SSRI exposure may impact early fetal motor
development that is self-limiting later in infancy and young toddlerhood due possibly to a
washout effect, however our study and other studies [103, 104] indicate that motor
impairment might persist to the ages of two to five years. Therefore further follow-up
studies are needed to clarify the persistence of fetal SSRI exposure on motor
development in children. This finding was not completely unanticipated since the role of
serotonin is essential in the maturation of the sensorimotor areas during development,
including the cerebellum, basal ganglia and those areas innervated by and under the
control of serotonergic fibers [159].
We observed a difference margin of approximately 3 points in the communication
and personal/social domains between the SSRI subgroup versus both the Depressive
Symptoms and Reference group. Again, whether this 3-point difference is statistically or
clinically significant is inconclusive, however these potential developmental deficits are
supported by previous observational and animal model studies. A recent large Norwegian
population-based cohort study reported that prolonged in utero SSRI exposure was
associated with moderate language delays in 3 year olds independent of the underlying
maternal depression before, during, and after pregnancy [111]. However the authors
suggested moderate language delay may later resolve since severe language delay or
clinical delay was not included as part of the outcome. No other studies to date have
found an association between communication or language delay and antenatal SSRI
exposure [101, 102, 109, 115]. Therefore even if our result was statistically significant,
the clinical importance for communication deficit is unlikely based on evidence from the
literature.
In addition, the majority of studies suggested that antenatal SSRI exposure was
not associated with an increased risk of personal/social behavioural problems in children
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[9, 10, 13, 101, 102, 106, 107], although, a few observational [12, 104, 108, 110] and
animal studies [160, 161] did find such an association. For example, previous
observational research has illustrated that antenatal exposure to SSRIs was associated
with increased risk of lower Behavior Rating Score (orientation/engagement, emotional
regulation, and motor quality) in a small sample of 12 to 40 month olds [104], inability to
occupy themselves alone for 15 minutes (attention) in 19 month olds after controlling for
postnatal depressive symptoms [12], and higher levels of internalizing behaviour
(withdrawal, anxiety, depression) in 3 and 6 year olds after controlling maternal mood
during antenatal, postnatal, and childhood period [110]. In animal models, the early
administration of SSRIs in neonates and the subsequent increase in serotonin level have
been shown to cause permanent impairment in the neural connection of the
somatosensory cortex, as well as impairment in social behaviours such as reduced
exploratory behaviour and depressive and anxiety-related behaviour in adulthood [160,
161]. Recently, in utero SSRI exposure was found to be associated with a change in
serum concentration of proteins such as reelin and activin A that are imperative in early
neurodevelopment during gestation in humans [124, 125].
Since our analysis was descriptive, there remains a significant possibility for
confounding variables such as the severity of underlying antenatal and postnatal maternal
psychiatric illnesses and its related behaviours to affect our findings in the long-term
development of children. For instance, Nulman et al. [9] reported that children exposed to
SSRIs had a lower IQ compared to children not exposed to SSRIs. However, regression
analysis discovered that the severity of maternal depression during and after pregnancy
and maternal IQ predicted problematic behaviour and cognitive outcomes, respectively,
while duration and dose of antidepressant exposure during pregnancy did not predict
developmental outcomes. Similarly, Misri et al. [107] discovered that current maternal
depression and anxiety were associated with increased internalizing behaviour and not
SSRI use. On the other hand, Oberlander et al. [105] found that antenatal exposure to
SSRIs in combination with current maternal anxiety were associated with an increased
rate of internalizing behavior at 3 years of age. This suggests that there may be a complex
association between underlying maternal mental disorders, medication use, and the longterm developmental outcome.
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At this point, the significance of our results on long-term development remains
uncertain and whether these “deficits” manifest in clinically relevant issues later in life is
even more unclear and doubtful. Based on the literature, this area of research is still in the
beginning stages without a definitive conclusion regarding the clinical relevance due to
the challenges in designing observational studies with adequate sample size that accounts
for residual confounding variables. However, the use of SSRIs during pregnancy could
increase the risk of some development delays involving psychomotor and personal/social
behavioural development with unknown clinical implications. The future direction for
this research area is discussed in section 5.5.
5.4 Strengths and Limitations
One of the main strengths of this study was the inclusion of women with
depressive symptoms but not taking antidepressants, which to some degree allowed us to
directly examine the effect of antidepressant exposure on neonatal and long-term
outcomes independent from potential underlying maternal illness and account for any
unmeasured or unidentified variables associated with having depressive symptoms. In
addition, women who participated in the PHP were unaware of the aim of this study when
filling out the ASQ, therefore participant bias was unlikely present. Another strength of
this study was the benefit of utilizing the well-designed PHP dataset, which prospectively
collected a plethora of information on relevant pregnancy exposures and neonatal and
child development outcomes. For instance, although clinical diagnosis of psychiatric
illnesses and its severity were unknown, the PHP utilized widely validated psychological
screening tests including the CES-D and STAI to identify individuals at risk for clinical
depression and to detect the incidence and severity of state anxiety symptoms,
respectively [162, 163]. Additionally, the CES-D is widely used in antenatal research and
recommended as an initial assessment for depressive symptoms during pregnancy [25].
Furthermore, we were able to use the Canadian population reference to account for
gestational age when examining birth weight where many previous studies had not done
so [21]. From the postnatal survey, 87.5% and 94.1% of women in the Antidepressant
group and SSRI subgroup, respectively reported past diagnosis of depression or mood
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disorder so it is likely that the indication of antidepressant use was for what it was
intended.
Given the PHP was not designed to investigate this specific thesis topic, we
acknowledge a number of limitations. As previously mentioned, we were unable to
produce precise risk estimates and control for confounding variables because of the small
number of women taking antidepressant in our study sample. This relatively low
prevalence of antidepressant use is comparable to many observational studies being one
of the common challenges in this research area. To compensate for the lack of robust
statistical analysis, this thesis provided a concise descriptive analysis and thorough
literature review on the neonatal and long-term outcomes of antidepressant use during
pregnancy. Furthermore, our method of controlling for confounding by indication for the
treatment may have introduced selection bias since women who opt for treatment during
pregnancy may be inherently different from women who do not receive treatment during
pregnancy. For instance, it is probable that women with more severe psychiatric illness
were required to continue their treatment during pregnancy, which may have
overestimated the impact of antidepressant use on neonatal and long-term developmental
outcomes. Ramos et al. [50] support this notion by reporting that pregnant women who
initiate or continue antidepressant treatment were more likely to have a higher number of
prescribers, a higher number of visits to the doctors before pregnancy, and a depression
diagnosis before or during pregnancy.
The potential for misclassification of variables due to self-reporting and recall
bias needs to be recognized. Specifically, self-reported height and weight used for the
calculation of pre-pregnancy BMI might be underestimated from the overestimation of
height and underestimation of weight. Misclassification of weight gained during
pregnancy also needs to be addressed because it was captured as a categorical variable
without accounting for the recommended weight gain based on the maternal BMI. For
instance, the recommended range of total weight gain during pregnancy for an
overweight woman is 15-25lbs and using our categorization would misclassify their
weight gain as appropriate (21lbs-39lbs) [149]. Antidepressant medication use was also
self-reported by participants, however they were asked to list all the medication used

75
currently at the time of the survey as well as the amount and frequency of use thereby
reducing the likelihood of recall bias.
The ASQ is a validated developmental screening tool compared to other
professionally administered assessments such as the Bayley Scale of Infant Development
[164]. However, the reliance on the ASQ to assess child developmental is another
limitation worth mentioning since we did not utilize the ASQ as it was intended as a
dichotomized outcome (pass or fail) test. Nonetheless, the intention was not to investigate
the individual pass or fail but to utilize the continuous ASQ scores for its ability to
compare scores among different groups. The ASQ may also underestimate developmental
delays and generally identify development as normal given the evidence of the negative
skew distribution and ceiling effect in our sample population. The benefit, however, of
utilizing the ASQ is that it can be self-administered quickly and easily at home by parents
[164].
In addition, self-reported evaluation of child development using the ASQ might
have been influenced by maternal mood because psychologically distressed mothers have
the propensity to over-report or underreport their child development resulting in
inaccurate assessment [165, 166]. Furthermore, developmental assessment was reported
at a single time point, which might have restricted our result, as child development is
likely to change over time. On a related note, whether depressive symptoms persists
throughout pregnancy or discontinues is unknown given CES-D was utilized at a single
time frame. However, depressive symptoms have been found to persist and remain
uniform through pregnancy [167]. Lastly, this is an observational study, therefore the
direction of effect or causality between exposure and outcome cannot be confirmed.
5.5 Conclusion and Future Directions
The main goal of this thesis was to differentiate the effect of antenatal
antidepressant exposure from that of antenatal maternal depressive symptoms on neonatal
health and subsequent long-term development. By doing so, our univariable results
suggests that newborns exposed to antidepressants and SSRIs in utero had an increased
risk of being LGA compared to infants born to untreated women with depressive
symptoms and healthy women. However, this could be explained by third-variable

76
factors including high pre-pregnancy BMI possibly induced by the combination of
antidepressant use and underlying depression. Additionally, newborns exposed to SSRIs
in utero had an increased risk of being preterm compared to infants born to healthy
women. We also observed lower mean ASQ scores in the fine motor, gross motor,
communication, and personal/social domains among children exposed to in utero SSRIs
in our descriptive analysis. Our findings contribute to the growing literature on antenatal
antidepressant use and its potential risks, yet it is important to acknowledge that these
findings are still tentative and further studies with larger sample size are needed.
In this

area of research, it

is

challenging to

design observational

pharmacoepidemiological studies without encountering some level of confounding by
indication, residual confounding, and small sample size of exposure group. In addition,
the heterogeneity of study design across the literature makes it extremely difficult to
formulate any conclusions on the risk or benefits of antidepressant use during pregnancy
for clinical recommendations. For instance, currently there is not a single meta-analysis
on antidepressant exposure during pregnancy and its effect on child development due to
the diverse methodologies and outcome measures in the literature.
Thus, in order for advancement in this field of research, new strategies are
needed, especially for the investigation of long-term developmental outcomes. Recently,
sibling discordance designs have been implemented that allowed for the control of
familial and genetic factors, however this design is limited by sample size and potential
bias by other discordance factors [168]. Another approach is to include participants
receiving different antidepressant medication for the same underling disease, however
cross interaction of neurotransmitters limits this method. Perhaps, then, well-designed
randomized controlled trials (RCTs) are the future direction for this area of research as
recommended by El Marroun et al. [145], since RCTs are immune from confounding by
indication. They advise recruiting women who are planning for pregnancy and
considering the cessation of their maintenance pharmacotherapy in order to address the
ethical dilemma. Moreover, future studies, albeit extremely difficult, need to include the
importance and complexity of genetic polymorphism of cytochrome P450 enzymes
(CYPs) as different CYPs metabolize certain antidepressants more effectively which
could provide an explanation for the difference in study outcomes [169].

77
Overall the results from this thesis do not warrant any changes in the current
clinical practices nor diminish the importance of antidepressant treatment in cases of
recurrent and severe depression; however, our results will bring awareness of the possible
risks of antidepressant use and contribute to the developing literature. There are indeed
complex challenges in treating depression and other psychiatric illness during pregnancy
due to the potential unwanted drug effects and unwanted effect of untreated depression
on the offspring. Ultimately, it is crucial for clinicians to thoroughly discuss the risk and
benefits of the specific antidepressant treatment during pregnancy to patients on a caseby-case basis for patients to make well-informed decisions for the well-being of both the
mothers and their children.
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Appendices
Appendix A: Animal model literature review
In rodent studies, the phenomenon of paradoxical behaviour outcomes has been
noted, meaning that SSRIs administered during early neurodevelopmental period
(antenatal, neonatal, and adolescent) causes anxiety- and depression-like behaviours in
adulthood, whereas SSRI exposure during adulthood has the opposite behavioural effects
[1]. This observed paradox is likely explained by SSRI-induced changes in neural
serotonin levels during critical neurodevelopment periods [2].
A study conducted by Hansen et al. [3] was the first to find an adverse long-term
neurobehavioural effect of SSRI exposure. SSRIs were administered during 8th to 21st
postnatal days, which corresponded to the events of brain maturation that began during
the third trimester of pregnancy and early childhood in humans. At the age of fourth
months, both saline- and SSRI-treated groups were assessed in open field, forced swim,
and social interaction tests. A significant difference was only found in the forced swim
test where the SSRI-treated group had a prolonged immobility time, which was purported
to represent behavioural despair and negative mood. This result indicates that the central
serotonergic system play a role in the pathology of depression.
An innovative study performed by Ansorge et al. [4] administered fluoxetine or
saline postnatally from day 4 to 21 for mice of different serotonin transport (5-HTT)
genotypes. Tests were conducted 9 weeks after the last injection of fluoxetine or saline.
Decreased exploratory behaviours, longer latencies to begin feeding, and longer average
latency to escape foot shock were observed in wildtype (5-HTT+/+) and heterozygous (5HTT+/-) mice treated with fluoxetine compared to those treated with saline. Similar
behaviours were detected in mutated (5-HTT-/-) mice that were treated with either
fluoxetine or saline. These results suggest that alteration of neural serotonin level either
by permanent genetic modification of 5-HTT or transient SSRI treatments during critical
neurodevelopment periods changes the neural connections in the central nervous system
(CNS) that regulate depression- and anxiety-related behaviours in adulthood.
Increased neural serotonin concentration during the neurodevelopmental stages
may also affect aggression in adulthood. Manhães de Castro et al. [5] investigated the
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degree of aggression in adult mice (90-120 days old) exposed to citalopram from 1st to
19th postnatal days. The duration of aggressive behaviour in the mice treated with
citalopram decreased by 41.4% compared to the control group. Additionally, Maciag et
al. [6] found decreased expression of tryptophan hydroxylase (rate-limiting serotonin
synthetic enzyme) and 5-HTT in the CNS of adult mice exposed to citalopram postnatally
(8-21 days). Motor movement activity and sexual behavior were increased and decreased,
respectively [6]. Another study found anatomical changes in the fine neural wiring of the
somatosensory cortex in adult rats exposed to fluoxetine postnatally (0-6 days) [7].
Consequently, behavioural deficits related to somatosensory, such as tactile impairment,
thermal perceptions delay, and locomotion activity reduction (exploratory behavioural
reduction), were observed [7].
Popa et al. [8] also discovered depression-like behaviours such as an increase in
rapid eye movement (REM) sleep and anhedonia in mice exposed to escitalopram during
early postnatal life. The depressive symptoms, however, improved after long-term
escitalopram treatment. Similar to the findings of Ansorge et al. [4], mice with
genetically deficient expression of 5-HTT had comparable depression-like symptoms as
the mice that were treated transiently with escitalopram during postpartum periods.
Bairy et al. [9] also reported transient motor development delay in rats exposed to
antenatal fluoxetine (6th to 20th day of pregnancy), but other behavioural outcomes were
not negatively affected. Interestingly, rats exposed to higher doses of fluoxetine
performed well in the water maze test, which suggested an improvement in cognitive
abilities, particularly in learning and memory. In a similar study, pups exposed to
antenatal SSRIs had anxiety-like behaviours accompanied with decrease in social
behaviours during adulthood, but behavioural despair, anhedonia, and abnormal sexual
behaviour were not detected [10]. Lastly, mice pups exposed to fluoxetine during
pregnancy and lactation had decreased ambulation, impulsivity (as demonstrated via the
intruder-resident test), and increased immobility time (forced swim test) [11].
In conclusion, the above-mentioned studies were suggestive of adverse
behavioural changes, specifically depression- and anxiety-like symptoms, which
developed in adult rodents exposed to SSRIs during crucial neurodevelopment phases.
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Appendix B: Conceptual model
Figure B1: Conceptual model based on literature review: neonatal and developmental outcomes of antenatal depressive
symptoms and antidepressant exposure
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Appendix C: Relevant Sections from the Prenatal Health Project Questionnaire.
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